Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
26,000 | 2017-09-08 00:00:00 UTC | Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-glaxosmithkline-plc-2017-09-08 | null | null | Big drugmaker. High dividend yield. Promising new products.
All three apply to AbbVie Inc. (NYSE: ABBV) . They also all apply to GlaxoSmithKline plc (NYSE: GSK) . But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline's share price isn't very far above where it started out the year. Past perfor... | But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline's share price isn't very far above where it started out the year. AbbVie's pipeline is so loaded that it was ranked third among all big pharma companies by market research firm EvaluatePharma. All three apply to AbbVie Inc. (NYSE: ABBV) . | I think AbbVie is the best dividend stock in big pharma , because this great yield combined with the company's excellent track record of dividend increases and its position for future dividend increases. All three apply to AbbVie Inc. (NYSE: ABBV) . But while AbbVie stock has achieved solid gains so far in 2017, GlaxoS... | But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline's share price isn't very far above where it started out the year. The case for AbbVie Since high dividend yield and promising new products were already mentioned, let's first take a look at where AbbVie stands on both. I think AbbVie is the... | But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline's share price isn't very far above where it started out the year. I think AbbVie is the best dividend stock in big pharma , because this great yield combined with the company's excellent track record of dividend increases and its position f... |
26,001 | 2017-09-08 00:00:00 UTC | Notable Friday Option Activity: XL, ABBV, COST | ABBV | https://www.nasdaq.com/articles/notable-friday-option-activity-xl-abbv-cost-2017-09-08 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in XL Group Ltd (Symbol: XL), where a total of 16,546 contracts have traded so far, representing approximately 1.7 million underlying shares. That amounts to about 81.6% of XL's average daily trading volume over the pas... | Particularly high volume was seen for the $87.50 strike call option expiring January 19, 2018 , with 4,154 contracts trading so far today, representing approximately 415,400 underlying shares of ABBV. Below is a chart showing XL's trailing twelve month trading history, with the $38 strike highlighted in orange: AbbVie ... | Below is a chart showing XL's trailing twelve month trading history, with the $38 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 33,868 contracts thus far today. That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 68.2% of A... | That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 68.2% of ABBV's average daily trading volume over the past month, of 5.0 million shares. Below is a chart showing XL's trailing twelve month trading history, with the $38 strike highlighted in orange: AbbVie Inc (... | Below is a chart showing COST's trailing twelve month trading history, with the $155 strike highlighted in orange: For the various different available expirations for XL options , ABBV options , or COST options , visit StockOptionsChannel.com. Below is a chart showing XL's trailing twelve month trading history, with th... |
26,002 | 2017-09-08 00:00:00 UTC | AbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb | ABBV | https://www.nasdaq.com/articles/abbvies-upadacitinib-meets-primary-endpoint-in-phase-iib-2017-09-08 | null | null | AbbVie 's ABBV shares have increased more than 6% after the company announced that its oral JAK-1 selective inhibitor, upadacitinib (ABT-494), met primary endpoints in a phase IIb study for treatment of adult patients with atopic dermatitis, also known as eczema. The company plans to advance the candidate into phase II... | AbbVie 's ABBV shares have increased more than 6% after the company announced that its oral JAK-1 selective inhibitor, upadacitinib (ABT-494), met primary endpoints in a phase IIb study for treatment of adult patients with atopic dermatitis, also known as eczema. AbbVie's shares have outperformed the industry year to d... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stocks to Consider AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Repor... | AbbVie 's ABBV shares have increased more than 6% after the company announced that its oral JAK-1 selective inhibitor, upadacitinib (ABT-494), met primary endpoints in a phase IIb study for treatment of adult patients with atopic dermatitis, also known as eczema. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote ... | AbbVie 's ABBV shares have increased more than 6% after the company announced that its oral JAK-1 selective inhibitor, upadacitinib (ABT-494), met primary endpoints in a phase IIb study for treatment of adult patients with atopic dermatitis, also known as eczema. AbbVie's shares have outperformed the industry year to d... |
26,003 | 2017-09-08 00:00:00 UTC | AbbVie Inc. (ABBV) in Focus: Stock Moves 6.1% Higher | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-in-focus%3A-stock-moves-6.1-higher-2017-09-08 | null | null | AbbVie Inc.ABBV was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company-as the stock is now up 14.4% in the past one-month time frame.
The m... | AbbVie Inc.ABBV was a big mover last session, as the company saw its shares rise more than 6% on the day. AbbVie currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Investors interested in the Medical sector may consider a better-ranked stock... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Investors interested in the Medical sector may consider a better-ranked stock like Merit Medical Systems, Inc. MMSI , which carries a Zacks Rank #1 (Strong Buy). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merit Medical Systems, In... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Investors interested in the Medical sector may consider a better-ranked stock like Merit Medical Systems, Inc. MMSI , which carries a Zacks Rank #1 (Strong Buy). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merit Medical Systems, In... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Investors interested in the Medical sector may consider a better-ranked stock like Merit Medical Systems, Inc. MMSI , which carries a Zacks Rank #1 (Strong Buy). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merit Medical Systems, In... |
26,004 | 2017-09-08 00:00:00 UTC | Regeneron's Cemiplimab Gains Breakthrough Therapy Status | ABBV | https://www.nasdaq.com/articles/regenerons-cemiplimab-gains-breakthrough-therapy-status-2017-09-08 | null | null | Regeneron Pharmaceuticals, Inc.REGN along with partner Sanofi SNY announced that the FDA has granted Breakthrough Therapy status to its experimental candidate, cemiplimab (REGN2810).
Sanofi/Regeneron are looking to get cemiplimab, a checkpoint inhibitor targeting PD-1 (programmed death 1), approved for treating adults ... | Significantly, shares of Regeneron have declined almost 6% despite the good news as AbbVie ABBV announced its skin treatment candidate upadacitinib to having met primary endpoints in phase IIb study which in turn might increase market competition for cemiplimab. Click to get this free report Sanofi (SNY): Free Stock An... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report To read this article on Zacks.com click here. Significantly, shares of R... | Significantly, shares of Regeneron have declined almost 6% despite the good news as AbbVie ABBV announced its skin treatment candidate upadacitinib to having met primary endpoints in phase IIb study which in turn might increase market competition for cemiplimab. Click to get this free report Sanofi (SNY): Free Stock An... | Significantly, shares of Regeneron have declined almost 6% despite the good news as AbbVie ABBV announced its skin treatment candidate upadacitinib to having met primary endpoints in phase IIb study which in turn might increase market competition for cemiplimab. Click to get this free report Sanofi (SNY): Free Stock An... |
26,005 | 2017-09-08 00:00:00 UTC | ABBV Crosses Above Average Analyst Target | ABBV | https://www.nasdaq.com/articles/abbv-crosses-above-average-analyst-target-2017-09-08 | null | null | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $77.90, changing hands for $81.78/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a h... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $77.90, changing hands for $81.78/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions ... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $77.90, changing hands for $81.78/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions ... | There are 10 different analyst targets contributing to that average for AbbVie Inc, but the average is just that - a mathematical average. And so with ABBV crossing above that average target price of $77.90/share, investors in ABBV have been given a good signal to spend fresh time assessing the company and deciding for... | There are 10 different analyst targets contributing to that average for AbbVie Inc, but the average is just that - a mathematical average. In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $77.90, changing hands for $81.78/share. But the whole reason ... |
26,006 | 2017-09-07 00:00:00 UTC | 5 Things Gilead Sciences' Management Just Said That You'll Want to Know | ABBV | https://www.nasdaq.com/articles/5-things-gilead-sciences-management-just-said-youll-want-know-2017-09-07 | null | null | Last week, Gilead Sciences (NASDAQ: GILD) generated plenty of buzz with the announcement of its planned acquisition of Kite Pharma (NASDAQ: KITE) . On Wednesday, several of the company's top executives sat down at the Citi biotech conference to field questions.
Gilead Sciences COO Kevin Young, chief scientific officer ... | AbbVie (NYSE: ABBV) won FDA approval for Mavyret in August. The bad news for Gilead is that AbbVie priced its new HCV drug at a steep discount to current drugs on the market. He also said that Gilead wasn't surprised by AbbVie's pricing. | AbbVie (NYSE: ABBV) won FDA approval for Mavyret in August. The bad news for Gilead is that AbbVie priced its new HCV drug at a steep discount to current drugs on the market. He also said that Gilead wasn't surprised by AbbVie's pricing. | AbbVie (NYSE: ABBV) won FDA approval for Mavyret in August. The bad news for Gilead is that AbbVie priced its new HCV drug at a steep discount to current drugs on the market. He also said that Gilead wasn't surprised by AbbVie's pricing. | He also said that Gilead wasn't surprised by AbbVie's pricing. AbbVie (NYSE: ABBV) won FDA approval for Mavyret in August. The bad news for Gilead is that AbbVie priced its new HCV drug at a steep discount to current drugs on the market. |
26,007 | 2017-09-07 00:00:00 UTC | AbbVie Inc (ABBV) Stock Surges on Positive Eczema Study | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-stock-surges-on-positive-eczema-study-2017-09-07 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) shares roared Thursday as the company unveiled strong results on its latest medication for eczema.
The biopharmaceutical company said on Thursday that its experimental drug designed to treat adults with moderate-to-severe eczema rea... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) shares roared Thursday as the company unveiled strong results on its latest medication for eczema. AbbVie's mid-stage trial data for its drug was comparable to Dupixent's late-stage data, suggesting it could be stronger than its riv... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) shares roared Thursday as the company unveiled strong results on its latest medication for eczema. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) shares roared Thursday as the company unveiled strong results on its latest medication for eczema. More From InvestorPlace 7 Non-Tech Stocks Using Tech to Win 7 Dividend Aristocrats to Buy for Growth, Too Amazon.com, Inc. (AMZN) Sto... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) shares roared Thursday as the company unveiled strong results on its latest medication for eczema. AbbVie's mid-stage trial data for its drug was comparable to Dupixent's late-stage data, suggesting it could be stronger than its riv... |
26,008 | 2017-09-07 00:00:00 UTC | Why Cabela's, Fitbit, and AbbVie Jumped Today | ABBV | https://www.nasdaq.com/articles/why-cabelas-fitbit-and-abbvie-jumped-today-2017-09-07 | null | null | The stock market was mixed on Thursday, with the major U.S. indexes closing the session almost flat. Concerns about the damage Hurricane Irma will inflict when it hits the Florida coast this weekend continued to weigh on certain sectors, but a moment of bipartisanship in Washington made generated some optimism about th... | Some individual stocks also delivered good news for investors, and Cabela's (NYSE: CAB) , Fitbit (NYSE: FIT) , and AbbVie (NYSE: ABBV) were among the best performers on the day. AbbVie gets some good news Finally, AbbVie shares gained 6.1%. AbbVie management saw the news as good, and with the drug also in phase 3 trial... | Some individual stocks also delivered good news for investors, and Cabela's (NYSE: CAB) , Fitbit (NYSE: FIT) , and AbbVie (NYSE: ABBV) were among the best performers on the day. AbbVie gets some good news Finally, AbbVie shares gained 6.1%. AbbVie management saw the news as good, and with the drug also in phase 3 trial... | Some individual stocks also delivered good news for investors, and Cabela's (NYSE: CAB) , Fitbit (NYSE: FIT) , and AbbVie (NYSE: ABBV) were among the best performers on the day. AbbVie gets some good news Finally, AbbVie shares gained 6.1%. AbbVie management saw the news as good, and with the drug also in phase 3 trial... | Some individual stocks also delivered good news for investors, and Cabela's (NYSE: CAB) , Fitbit (NYSE: FIT) , and AbbVie (NYSE: ABBV) were among the best performers on the day. AbbVie gets some good news Finally, AbbVie shares gained 6.1%. AbbVie management saw the news as good, and with the drug also in phase 3 trial... |
26,009 | 2017-09-07 00:00:00 UTC | AbbVie Scores 2 Wins: 1 Threatens Regeneron | ABBV | https://www.nasdaq.com/articles/abbvie-scores-2-wins-1-threatens-regeneron-2017-09-07 | null | null | AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial data for upadacitinib in eczema patients.
The patent victory could help AbbVie delay entrance of biosimilars to its top-selli... | AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial data for upadacitinib in eczema patients. One of the most intriguing of its R&D projects is JAK1 inhibitor upadacitinib, and ... | The patent victory could help AbbVie delay entrance of biosimilars to its top-selling Humira, while the upadacitinib data puts AbbVie on track to challenge Regeneron Pharmaceuticals ' (NASDAQ: REGN) recently launched eczema drug , Dupixent. AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a vi... | AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial data for upadacitinib in eczema patients. The patent victory could help AbbVie delay entrance of biosimilars to its top-selli... | The patent victory could help AbbVie delay entrance of biosimilars to its top-selling Humira, while the upadacitinib data puts AbbVie on track to challenge Regeneron Pharmaceuticals ' (NASDAQ: REGN) recently launched eczema drug , Dupixent. AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a vi... |
26,010 | 2017-09-07 00:00:00 UTC | AbbVie Submits NDA for Endometriosis Candidate to the FDA | ABBV | https://www.nasdaq.com/articles/abbvie-submits-nda-for-endometriosis-candidate-to-the-fda-2017-09-07 | null | null | AbbVie Inc.ABBV and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA. AbbVie is looking to get elagolix approved as an oral medicine for the management of pain associated with endometriosis.
The NDA filing is supported by ... | Apart from elagolix, AbbVie has several candidates in different stages of development across a wide range of therapeutic areas and has partnerships with companies like Roche RHHBY , Bristol-Myers BMY and Biogen BIIB . AbbVie Inc.ABBV and partner Neurocrine Biosciences announced that the new drug application (NDA) for t... | Apart from elagolix, AbbVie has several candidates in different stages of development across a wide range of therapeutic areas and has partnerships with companies like Roche RHHBY , Bristol-Myers BMY and Biogen BIIB . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squib... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV and partner Neuroc... | AbbVie Inc.ABBV and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA. AbbVie is looking to get elagolix approved as an oral medicine for the management of pain associated with endometriosis. So far this year, AbbVie's shar... |
26,011 | 2017-09-07 00:00:00 UTC | Vanguard High Dividend Yield ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/vanguard-high-dividend-yield-etf-experiences-big-inflow-2017-09-07 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $63.5 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 237,587,... | Among the largest underlying components of VYM, in trading today International Business Machines Corp (Symbol: IBM) is trading flat, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is up by about 2.5%. For a complete list of holdings, visit the VYM Holdings page » The chart below sho... | Among the largest underlying components of VYM, in trading today International Business Machines Corp (Symbol: IBM) is trading flat, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is up by about 2.5%. For a complete list of holdings, visit the VYM Holdings page » The chart below sho... | Among the largest underlying components of VYM, in trading today International Business Machines Corp (Symbol: IBM) is trading flat, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is up by about 2.5%. Looking today at week-over-week shares outstanding changes among the universe of E... | Among the largest underlying components of VYM, in trading today International Business Machines Corp (Symbol: IBM) is trading flat, Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is up by about 2.5%. Looking today at week-over-week shares outstanding changes among the universe of E... |
26,012 | 2017-09-06 00:00:00 UTC | Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead | ABBV | https://www.nasdaq.com/articles/forget-abbott-buy-these-4-high-growth-medtech-stocks-instead-2017-09-06 | null | null | Lately, the MedTech space has been facing the brunt of frequent regulatory changes. While the Trump administration is faced with a socio-economic upheaval, investors are apprehensive about its impact on stocks.
Historic trends suggest that investor sentiments have always been partially inclined toward fancy brand names... | Among its strategic buyouts, the acquisitions of CFR Pharmaceuticals, Tendyne Holdings, and St. Jude Medical are worth mentioning After spinning off its proprietary pharmaceutical products division in 2013 to form AbbVie Inc. ABBV , Abbott has gained traction in the Established Pharmaceuticals Division. Click to get th... | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report LeMaitre Vascular, Inc. (LMAT): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Lonza Gr... | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report LeMaitre Vascular, Inc. (LMAT): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Lonza Gr... | Among its strategic buyouts, the acquisitions of CFR Pharmaceuticals, Tendyne Holdings, and St. Jude Medical are worth mentioning After spinning off its proprietary pharmaceutical products division in 2013 to form AbbVie Inc. ABBV , Abbott has gained traction in the Established Pharmaceuticals Division. Click to get th... |
26,013 | 2017-09-04 00:00:00 UTC | Revealed: The Secret to Safe 12% Yearly Gains … for Life | ABBV | https://www.nasdaq.com/articles/revealed-secret-safe-12-yearly-gains-life-2017-09-04 | null | null | By Brett Owens
Don't let the pundits deceive you. Despite their endless bleating about an overheated market and an imminent crash, now is a great time to buy.
But you need to look beyond the breathless reporting about the S&P 500's daily push higher--or its ratchet-tight P/E ratio.
Because the real winning stocks are c... | Stick with me for a moment and I'll show what I mean using biotech player AbbVie ( ABBV ), a stock I recommended on June 2 . If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield. B... | AbbVie also pays out 59% of earnings per share as dividends--easily manageable in light of rising adjusted earnings per share (up 12.7% year-over-year in Q2). Stick with me for a moment and I'll show what I mean using biotech player AbbVie ( ABBV ), a stock I recommended on June 2 . If you bought AbbVie in January 2014... | If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield. Stick with me for a moment and I'll show what I mean using biotech player AbbVie ( ABBV ), a stock I recommended on June 2 . B... | Stick with me for a moment and I'll show what I mean using biotech player AbbVie ( ABBV ), a stock I recommended on June 2 . If you bought AbbVie in January 2014, a year after it was spun off from Abbott Labs ( ABT ), you were pocketing a $0.40 quarterly dividend, good for a 3.2% trailing-twelve-month dividend yield. B... |
26,014 | 2017-09-03 00:00:00 UTC | Here's the Best Dividend Stock in Big Pharma | ABBV | https://www.nasdaq.com/articles/heres-best-dividend-stock-big-pharma-2017-09-03 | null | null | Dividends make a huge impact on your overall investing returns. They can also provide solid income during your retirement years. Historically, big pharma stocks have been a great place for investors to turn to for high yields and reliable income.
But which big pharma stock is the best dividend stock of all? I looked at... | After reviewing all of them, my conclusion is that the best dividend stock in big pharma is (drum roll, please) AbbVie (NYSE: ABBV) . Here's why AbbVie beat out all the others. Look at the forest, not the trees AbbVie doesn't have the highest dividend yield among big pharma stocks. | Look at the forest, not the trees AbbVie doesn't have the highest dividend yield among big pharma stocks. After reviewing all of them, my conclusion is that the best dividend stock in big pharma is (drum roll, please) AbbVie (NYSE: ABBV) . Here's why AbbVie beat out all the others. | Look at the forest, not the trees AbbVie doesn't have the highest dividend yield among big pharma stocks. But Gilead's yield of 2.82% is well below AbbVie's, so the big biotech didn't fare well enough overall to be the best big pharma dividend stock. Runners-up The combination of one of the highest yields with what app... | Runners-up The combination of one of the highest yields with what appears to be the greatest likelihood of further dividend increases makes AbbVie the clear winner, in my view, as the best big pharma dividend stock. After reviewing all of them, my conclusion is that the best dividend stock in big pharma is (drum roll, ... |
26,015 | 2017-08-30 00:00:00 UTC | The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-kite-pharma-abbvies-and-novartis-ag | null | null | For Immediate Release
Chicago, IL - August 30, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Gilead Sciences, Inc. (NASDA... | Stocks recently featured in the blog include Gilead Sciences, Inc. (NASDAQ: GILD - Free Report ), Kite Pharma, Inc. (NASDAQ: KITE - Free Report ), AbbVie's (NYSE: ABBV - Free Report ) and Novartis AG (NYSE: NVS - Free Report ). We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's (NYSE: ABBV - Free ... | Stocks recently featured in the blog include Gilead Sciences, Inc. (NASDAQ: GILD - Free Report ), Kite Pharma, Inc. (NASDAQ: KITE - Free Report ), AbbVie's (NYSE: ABBV - Free Report ) and Novartis AG (NYSE: NVS - Free Report ). Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABB... | Stocks recently featured in the blog include Gilead Sciences, Inc. (NASDAQ: GILD - Free Report ), Kite Pharma, Inc. (NASDAQ: KITE - Free Report ), AbbVie's (NYSE: ABBV - Free Report ) and Novartis AG (NYSE: NVS - Free Report ). Get the full Report on KITE - FREE Get the full Report on GILD - FREE Get the full Report on... | Stocks recently featured in the blog include Gilead Sciences, Inc. (NASDAQ: GILD - Free Report ), Kite Pharma, Inc. (NASDAQ: KITE - Free Report ), AbbVie's (NYSE: ABBV - Free Report ) and Novartis AG (NYSE: NVS - Free Report ). We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's (NYSE: ABBV - Free ... |
26,016 | 2017-08-30 00:00:00 UTC | Has Gilead Sciences' Big Bounce Begun With the Kite Pharma Buyout? | ABBV | https://www.nasdaq.com/articles/has-gilead-sciences-big-bounce-begun-kite-pharma-buyout-2017-08-30 | null | null | Once upon a time, Gilead Sciences (NASDAQ: GILD) was one of the hottest biotech stocks on the market. But for most of the last two years, Gilead was anything but hot, with its market cap losing nearly half of its value at one point. The company in many respects was a victim of its own success, with previous growth from... | And Gilead faces a new challenge in hep-C: AbbVie won U.S. approval for its pan-genotypic drug, Mavyret, in early August. *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. In its press release announcing the Kite Pharma buyout, Gilead Sciences stated that the acquisit... | *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. And Gilead faces a new challenge in hep-C: AbbVie won U.S. approval for its pan-genotypic drug, Mavyret, in early August. Once upon a time, Gilead Sciences (NASDAQ: GILD) was one of the hottest biotech stocks on the ma... | And Gilead faces a new challenge in hep-C: AbbVie won U.S. approval for its pan-genotypic drug, Mavyret, in early August. *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. Don't count on it Naysayers can make a pretty compelling argument that the Kite acquisition won'... | And Gilead faces a new challenge in hep-C: AbbVie won U.S. approval for its pan-genotypic drug, Mavyret, in early August. *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. Gilead said the deal should be neutral to earnings by year three. |
26,017 | 2017-08-29 00:00:00 UTC | Noteworthy ETF Inflows: IUSG, MA, MO, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows-iusg-ma-mo-abbv-2017-08-29 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $34.5 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 52,400,... | Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 0.3%, Altria Group Inc (Symbol: MO) is up about 0.7%, and AbbVie Inc (Symbol: ABBV) is up by about 0.1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 0.3%, Altria Group Inc (Symbol: MO) is up about 0.7%, and AbbVie Inc (Symbol: ABBV) is up by about 0.1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 0.3%, Altria Group Inc (Symbol: MO) is up about 0.7%, and AbbVie Inc (Symbol: ABBV) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... | Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 0.3%, Altria Group Inc (Symbol: MO) is up about 0.7%, and AbbVie Inc (Symbol: ABBV) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... |
26,018 | 2017-08-29 00:00:00 UTC | The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbvie-broadcom-21st-century-fox-intuit-and-china-life | null | null | For Immediate Release
Chicago, IL - August 29, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Re... | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ), 21st Century Fox (NASDAQ: FOXA - Free Report ), Intuit (NASDAQ: INTU - Free Report ) and China Life Insurance (NYSE: LFC - Free Report ). Here are highlights from Monday's Analyst Blog: Top Analyst R... | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ), 21st Century Fox (NASDAQ: FOXA - Free Report ), Intuit (NASDAQ: INTU - Free Report ) and China Life Insurance (NYSE: LFC - Free Report ). Today's Research Daily features new research reports on 16 ma... | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ), 21st Century Fox (NASDAQ: FOXA - Free Report ), Intuit (NASDAQ: INTU - Free Report ) and China Life Insurance (NYSE: LFC - Free Report ). Get the full Report on ABBV - FREE Get the full Report on AVG... | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), Broadcom (NASDAQ: AVGO - Free Report ), 21st Century Fox (NASDAQ: FOXA - Free Report ), Intuit (NASDAQ: INTU - Free Report ) and China Life Insurance (NYSE: LFC - Free Report ). Here are highlights from Monday's Analyst Blog: Top Analyst R... |
26,019 | 2017-08-29 00:00:00 UTC | Gilead to Fly High with Kite Pharma Acquisition for $11.9B | ABBV | https://www.nasdaq.com/articles/gilead-to-fly-high-with-kite-pharma-acquisition-for-%2411.9b-2017-08-29 | null | null | Biotech giant Gilead Sciences, Inc.GILD announced that it will buy Kite Pharma, Inc. KITE to foray into the emerging field of cell therapy.
Terms of the Agreement
As per the agreement, Gilead will pay $180.00 per share in cash at a transaction valued at approximately $11.9 billion. The price represents a 28% premium ov... | We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Viekira XR, among others. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (K... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa... | We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Viekira XR, among others. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (K... |
26,020 | 2017-08-28 00:00:00 UTC | Roche's Gazyva Gets Priority Review for Follicular Lymphoma | ABBV | https://www.nasdaq.com/articles/roches-gazyva-gets-priority-review-for-follicular-lymphoma-2017-08-28 | null | null | Roche Holding AGRHHBY announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to Gazyva in combination with chemotherapy followed by Gazyva alone for patients suffering from previously untreated follicular lymphoma.
The FDA is expected announce its... | Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie Inc. ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Click to get this free report Roche Holding AG (RHHBY... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report To read this article on Zacks.com click here. Roche's hematology portfolio at ... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report To read this article on Zacks.com click here. Roche's hematology portfolio at ... | Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie Inc. ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Click to get this free report Roche Holding AG (RHHBY... |
26,021 | 2017-08-28 00:00:00 UTC | HRS Investment Holdings, LLC Buys Athene Holding, Goldman Sachs Group Inc, The Kroger Co, Sells ... | ABBV | https://www.nasdaq.com/articles/hrs-investment-holdings-llc-buys-athene-holding-goldman-sachs-group-inc-kroger-co-sells | null | null | HRS Investment Holdings, LLC
New Purchases: GS , KR , NYLD , CIT, ARNC, FANG, FN, DG, M, CLDR,
Added Positions:ATH, TAP, LYB, GM, SLCA, JPM, EOG, FIVE, AAPL, ABBV,
Reduced Positions:EW, FOE, QCOM, KORS, PYPL, STZ, HAIN, WBA, KATE,
Sold Out:AGN, AFSI, VIRT, APC, BBY, ZBH, SYT, RAD, TWTR , BBRY,
For the details of HRS In... | HRS Investment Holdings, LLC New Purchases: GS , KR , NYLD , CIT, ARNC, FANG, FN, DG, M, CLDR, Added Positions:ATH, TAP, LYB, GM, SLCA, JPM, EOG, FIVE, AAPL, ABBV, Reduced Positions:EW, FOE, QCOM, KORS, PYPL, STZ, HAIN, WBA, KATE, Sold Out:AGN, AFSI, VIRT, APC, BBY, ZBH, SYT, RAD, TWTR , BBRY, For the details of HRS In... | HRS Investment Holdings, LLC New Purchases: GS , KR , NYLD , CIT, ARNC, FANG, FN, DG, M, CLDR, Added Positions:ATH, TAP, LYB, GM, SLCA, JPM, EOG, FIVE, AAPL, ABBV, Reduced Positions:EW, FOE, QCOM, KORS, PYPL, STZ, HAIN, WBA, KATE, Sold Out:AGN, AFSI, VIRT, APC, BBY, ZBH, SYT, RAD, TWTR , BBRY, For the details of HRS In... | HRS Investment Holdings, LLC New Purchases: GS , KR , NYLD , CIT, ARNC, FANG, FN, DG, M, CLDR, Added Positions:ATH, TAP, LYB, GM, SLCA, JPM, EOG, FIVE, AAPL, ABBV, Reduced Positions:EW, FOE, QCOM, KORS, PYPL, STZ, HAIN, WBA, KATE, Sold Out:AGN, AFSI, VIRT, APC, BBY, ZBH, SYT, RAD, TWTR , BBRY, For the details of HRS In... | HRS Investment Holdings, LLC New Purchases: GS , KR , NYLD , CIT, ARNC, FANG, FN, DG, M, CLDR, Added Positions:ATH, TAP, LYB, GM, SLCA, JPM, EOG, FIVE, AAPL, ABBV, Reduced Positions:EW, FOE, QCOM, KORS, PYPL, STZ, HAIN, WBA, KATE, Sold Out:AGN, AFSI, VIRT, APC, BBY, ZBH, SYT, RAD, TWTR , BBRY, For the details of HRS In... |
26,022 | 2017-08-28 00:00:00 UTC | How to Retire on 8% Dividends Paid Monthly | ABBV | https://www.nasdaq.com/articles/how-retire-8-dividends-paid-monthly-2017-08-28 | null | null | By Brett Owens
The suits at Merrill Lynch say you need $738,400 to retire well.
Let me explain why they're dead wrong. You'll actually need a lotless than that.
I'm going to show you a simple way to bankroll your golden years on 32% less. That's right: I'm talking about a fully paid for retirement for around $500,000.
... | Here's an "instant" 6-stock monthly dividend portfolio that fits the bill: AT&T ( T )and AbbVie ( ABBV )-- two of the highest-yielding Aristocrats, with payouts of 5.2% and 3.6%, respectively--pay in February, May, August and November. First I want to show you... HowNotto Build a Solid Monthly Income Stream When it com... | Here's an "instant" 6-stock monthly dividend portfolio that fits the bill: AT&T ( T )and AbbVie ( ABBV )-- two of the highest-yielding Aristocrats, with payouts of 5.2% and 3.6%, respectively--pay in February, May, August and November. But here's the problem: these folks are forgetting that companies don't need a high ... | Here's an "instant" 6-stock monthly dividend portfolio that fits the bill: AT&T ( T )and AbbVie ( ABBV )-- two of the highest-yielding Aristocrats, with payouts of 5.2% and 3.6%, respectively--pay in February, May, August and November. Worse, that yield is in free-fall as stocks grind higher: The Aristocrats' (Not So) ... | Here's an "instant" 6-stock monthly dividend portfolio that fits the bill: AT&T ( T )and AbbVie ( ABBV )-- two of the highest-yielding Aristocrats, with payouts of 5.2% and 3.6%, respectively--pay in February, May, August and November. Worse, that yield is in free-fall as stocks grind higher: The Aristocrats' (Not So) ... |
26,023 | 2017-08-28 00:00:00 UTC | Gilead Sciences to Buy Kite Pharma for $11.9 Billion: Is It Enough to Move the Needle? | ABBV | https://www.nasdaq.com/articles/gilead-sciences-buy-kite-pharma-119-billion-it-enough-move-needle-2017-08-28 | null | null | What happened
Gilead Sciences (NASDAQ: GILD) , prompted by its falling sales of its hepatitis C drugs over the past year, has finally pulled the trigger on a much-anticipated buyout: On Monday, it offered to acquire Kite Pharma (NASDAQ: KITE) for $11.9 billion in an all-cash deal. Kite's shares were up by 28.87% in pre... | Sales of Gilead's hep C line are expected to nosedive in the next two to three years due to the emergence of a game-changing competing treatment from AbbVie. The biotech's lead CAR-T candidate, axicabtagene ciloleucel, or Axi-Cel for short, is currently under review by the U.S. Food and Drug Administration as a potenti... | Sales of Gilead's hep C line are expected to nosedive in the next two to three years due to the emergence of a game-changing competing treatment from AbbVie. What happened Gilead Sciences (NASDAQ: GILD) , prompted by its falling sales of its hepatitis C drugs over the past year, has finally pulled the trigger on a much... | Sales of Gilead's hep C line are expected to nosedive in the next two to three years due to the emergence of a game-changing competing treatment from AbbVie. What happened Gilead Sciences (NASDAQ: GILD) , prompted by its falling sales of its hepatitis C drugs over the past year, has finally pulled the trigger on a much... | Sales of Gilead's hep C line are expected to nosedive in the next two to three years due to the emergence of a game-changing competing treatment from AbbVie. Shares of fellow CAR-T developers Bellicum Pharmaceuticals (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) , and ZIOPHARM Oncology (NASDAQ: ZIOP) are all trad... |
26,024 | 2017-08-27 00:00:00 UTC | Why I Love AbbVie Inc. | ABBV | https://www.nasdaq.com/articles/why-i-love-abbvie-inc-2017-08-27 | null | null | "Where your treasure is, there will your heart be also."
Those profound words were spoken nearly 2,000 years ago. They were true then, and they're still true today. But even when your treasure is divided equally, some of the places where the money is placed will be closer to your heart than others.
That's the case for ... | If you include the time when AbbVie was part of Abbott Labs , the company claims an impressive streak of 44 consecutive years of dividend increases. That's the case for me with AbbVie (NYSE: ABBV) . AbbVie, though, is one of my favorites. | Promising experimental cancer drugs in AbbVie's pipeline include Rova-T and veliparib. *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. That's the case for me with AbbVie (NYSE: ABBV) . | AbbVie repurchased $7.8 billion worth of its stock in 2015 and $2.1 billion last year. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. | It's AbbVie's pipeline, though, that really excites investors. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's the case for me with AbbVie (NYSE: ABBV) . |
26,025 | 2017-08-26 00:00:00 UTC | Is the System Rigged Against Biosimilars? | ABBV | https://www.nasdaq.com/articles/system-rigged-against-biosimilars-2017-08-26 | null | null | If you think prescription drug costs are high now, imagine what costs would be without generic drugs. Roughly 25% of total prescription drug sales in 2016 were generics. But it's a different story altogether for biologics -- drugs made from living organisms or components of living organisms. Until 2010, biosimilars to ... | Even if AbbVie manages to fend off Amgen in court, it's just a matter of time before biosimilars begin chipping away at Humira's market share. Humira is the top-selling drug in the world, generating $16 billion for AbbVie (NYSE: ABBV) in 2016. AbbVie is on track to make even more money from Humira this year, despite th... | Humira is the top-selling drug in the world, generating $16 billion for AbbVie (NYSE: ABBV) in 2016. AbbVie is on track to make even more money from Humira this year, despite the approval for Amjevita. AbbVie is fighting Amgen in court, alleging patent infringement. | Even if AbbVie manages to fend off Amgen in court, it's just a matter of time before biosimilars begin chipping away at Humira's market share. Humira is the top-selling drug in the world, generating $16 billion for AbbVie (NYSE: ABBV) in 2016. AbbVie is on track to make even more money from Humira this year, despite th... | Humira is the top-selling drug in the world, generating $16 billion for AbbVie (NYSE: ABBV) in 2016. AbbVie is on track to make even more money from Humira this year, despite the approval for Amjevita. AbbVie is fighting Amgen in court, alleging patent infringement. |
26,026 | 2017-08-24 00:00:00 UTC | Roche (RHHBY) Hemophilia A Drug Granted Priority Review | ABBV | https://www.nasdaq.com/articles/roche-rhhby-hemophilia-a-drug-granted-priority-review-2017-08-24 | null | null | Roche Holding AGRHHBY announced that the FDA has accepted the company's Biologics License Application (BLA) and granted Priority Review for hemophilia A candidate, emicizumab.
The FDA has granted emicizumab prophylaxis (preventative) priority review as a once-weekly subcutaneous treatment for adults, adolescents and ch... | Along with emicizumab, Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie, Inc ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Click to get this free report ... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Along with emicizumab, Roche's hematology ... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Along with emicizumab, Roche's hematology ... | Along with emicizumab, Roche's hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie, Inc ABBV along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin. Click to get this free report ... |
26,027 | 2017-08-23 00:00:00 UTC | 3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences | ABBV | https://www.nasdaq.com/articles/3-reasons-abbvie-better-dividend-stock-gilead-sciences-2017-08-23 | null | null | Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one of the biggest biotechs on the planet, with a market cap of around $95 billion. But AbbVie is even bigger, with a market cap ... | But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. But AbbVie is even bigger, with a market cap topping $112 billion. There's one other key area where AbbVie holds an advantage over Gilead -- dividends. | The obvious First is the obvious reason: AbbVie has a higher dividend yield. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. But AbbVie is even bigger, with a market cap topping $112 billion. | However, here are three reasons why AbbVie is a better dividend stock than Gilead Sciences. While AbbVie is using 59% of earnings to fund its dividend program, Gilead is using less than 22% of its earnings to pay out dividends. AbbVie's past track record for dividends gives it another advantage over Gilead Sciences. | However, here are three reasons why AbbVie is a better dividend stock than Gilead Sciences. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. But AbbVie is even bigger, with a market cap topping $112 billion. |
26,028 | 2017-08-23 00:00:00 UTC | Top 3 Stocks for Retirees to Consider | ABBV | https://www.nasdaq.com/articles/top-3-stocks-retirees-consider-2017-08-23 | null | null | Retirement means you no longer need to work to make a living. But that doesn't mean your money needs to stop working for you. For those who know where to look, the stock market can be fantastic tool to make the most of your money after you retire.
So we asked three top Motley Fool investors to each pick a stock that th... | The healthcare giant that AbbVie spun off from, Abbott , is a dividend-paying legend, with 45 consecutive annual raises under its belt, and the maker of Humira looks well positioned to follow in its parent's footsteps for the foreseeable future. Read on to learn why they chose Tanger Factory Outlet Centers (NYSE: SKT) ... | Read on to learn why they chose Tanger Factory Outlet Centers (NYSE: SKT) , General Motors (NYSE: GM) , and AbbVie (NYSE: ABBV) . A big dividend from big drug sales Cory Renauer (AbbVie Inc.): Retirees looking for a healthy dividend should consider this big pharma stock and the 3.6% yield it offers at recent prices. Th... | A big dividend from big drug sales Cory Renauer (AbbVie Inc.): Retirees looking for a healthy dividend should consider this big pharma stock and the 3.6% yield it offers at recent prices. Read on to learn why they chose Tanger Factory Outlet Centers (NYSE: SKT) , General Motors (NYSE: GM) , and AbbVie (NYSE: ABBV) . Th... | Read on to learn why they chose Tanger Factory Outlet Centers (NYSE: SKT) , General Motors (NYSE: GM) , and AbbVie (NYSE: ABBV) . A big dividend from big drug sales Cory Renauer (AbbVie Inc.): Retirees looking for a healthy dividend should consider this big pharma stock and the 3.6% yield it offers at recent prices. Th... |
26,029 | 2017-08-21 00:00:00 UTC | iShares Russell 1000 Growth ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-1000-growth-etf-experiences-big-outflow-2017-08-21 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $48.2 million dollar outflow -- that's a 0.1% decrease week over week (from 295,450,000 to 295,050,000). ... | Among the largest underlying components of IWF, in trading today Mastercard Inc (Symbol: MA) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Celgene Corp. (Symbol: CELG) is lower by about 0.3%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of IWF, in trading today Mastercard Inc (Symbol: MA) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Celgene Corp. (Symbol: CELG) is lower by about 0.3%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of IWF, in trading today Mastercard Inc (Symbol: MA) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Celgene Corp. (Symbol: CELG) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel... | Among the largest underlying components of IWF, in trading today Mastercard Inc (Symbol: MA) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Celgene Corp. (Symbol: CELG) is lower by about 0.3%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price perf... |
26,030 | 2017-08-21 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Pfizer Inc. | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-pfizer-inc-2017-08-21 | null | null | There's no question that AbbVie (NYSE: ABBV) shareholders have been happier campers than Pfizer (NYSE: PFE) shareholders in recent years. Whether you compare the two drug stocks over five years, three years, one year, or so far in 2017, AbbVie stock has outperformed Pfizer.
But, as the statements read on mutual fund, p... | It's hard to beat AbbVie's triple whammy of great dividend, solid growth prospects, and attractive valuation. I still love Pfizer's dividend and think the stock is a good long-term pick, but AbbVie is the better buy. *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie and Pfizer. | AbbVie's top-selling drug, Humira, continues to enjoy solid sales momentum. AbbVie has several candidates that could prove to be megablockbusters in a few years, including cancer drug Rova-T, autoimmune disease drug ABT-494, and Elagolix, which targets treatment of endometriosis and uterine fibroids. It's hard to beat ... | Whether you compare the two drug stocks over five years, three years, one year, or so far in 2017, AbbVie stock has outperformed Pfizer. The case for Pfizer If you like AbbVie's dividend, you'll probably love Pfizer's. I still love Pfizer's dividend and think the stock is a good long-term pick, but AbbVie is the better... | Whether you compare the two drug stocks over five years, three years, one year, or so far in 2017, AbbVie stock has outperformed Pfizer. I still love Pfizer's dividend and think the stock is a good long-term pick, but AbbVie is the better buy. There's no question that AbbVie (NYSE: ABBV) shareholders have been happier ... |
26,031 | 2017-08-21 00:00:00 UTC | Vertex Pharmaceuticals Incorporated (VRTX) Stock Is Too Expensive | ABBV | https://www.nasdaq.com/articles/vertex-pharmaceuticals-incorporated-vrtx-stock-is-too-expensive-2017-08-21 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) has turned in triple-digit gains so far this year after news that the firm is on the verge of having several new cystic fibrosis treatments FDA approved. That's a big deal in the biotech world because trea... | AbbVie Inc (NYSE: ABBV ) and Galapagos NV (ADR) (NASDAQ: GLPG ) are working together on CF combination treatments of their own that could take away from the monumental projections for VRTX. However, new clinical trials show that a new drug, tezacaftor, together with Vertex's Kalydeco could be a successful combination t... | AbbVie Inc (NYSE: ABBV ) and Galapagos NV (ADR) (NASDAQ: GLPG ) are working together on CF combination treatments of their own that could take away from the monumental projections for VRTX. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) has turned in t... | AbbVie Inc (NYSE: ABBV ) and Galapagos NV (ADR) (NASDAQ: GLPG ) are working together on CF combination treatments of their own that could take away from the monumental projections for VRTX. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) has turned in t... | AbbVie Inc (NYSE: ABBV ) and Galapagos NV (ADR) (NASDAQ: GLPG ) are working together on CF combination treatments of their own that could take away from the monumental projections for VRTX. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) has turned in t... |
26,032 | 2017-08-20 00:00:00 UTC | 3 Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-id-buy-right-now-2017-08-20 | null | null | There's nothing more exciting on planet Earth than dividend stocks .
OK, I know that's laying it on thick. There are plenty of more exciting things. Still, though, dividend stocks are pretty exciting when you consider the long-term wealth they can generate. And there are more solid dividend stocks than you can shake a ... | *Stock Advisor returns as of August 1, 2017 Keith Speights owns shares of AbbVie. AT&T (NYSE: T) , Intel (NASDAQ: INTC) , and AbbVie (NYSE: ABBV) look especially attractive, in my view. AbbVie I like AbbVie so much that I already own the stock. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AT&T (NYSE: T) , Intel (NASDAQ: INTC) , and AbbVie (NYSE: ABBV) look especially attractive, in my view. AbbVie I like AbbVie so much that I already own the stock. | AT&T (NYSE: T) , Intel (NASDAQ: INTC) , and AbbVie (NYSE: ABBV) look especially attractive, in my view. AbbVie I like AbbVie so much that I already own the stock. If you like AT&T's track record for dividend increases, you'll probably love AbbVie. | AbbVie I like AbbVie so much that I already own the stock. AT&T (NYSE: T) , Intel (NASDAQ: INTC) , and AbbVie (NYSE: ABBV) look especially attractive, in my view. If you like AT&T's track record for dividend increases, you'll probably love AbbVie. |
26,033 | 2017-08-18 00:00:00 UTC | Rikoon Group, LLC Buys SPDR S&P Dividend, CVS Health Corp, Accenture PLC, Sells Smith & ... | ABBV | https://www.nasdaq.com/articles/rikoon-group-llc-buys-spdr-sp-dividend-cvs-health-corp-accenture-plc-sells-smith-2017-08 | null | null | Rikoon Group, LLC
New Purchases: SDY , ACN , ORAN ,
Added Positions:CVS, DG, DIS, LB, SPY, SHW, ORCL, AAP, AGN, CHL,
Reduced Positions:VZ, IMKTA, STO, SAP, AAPL, SHPG, GILD, TOT, XOM, SNY,
Sold Out:SNN, IWF, IWD, TGT, ABX, CNQ, SEP,
For the details of Rikoon Group, LLC's stock buys and sells, go to http://www.gurufocus... | AbbVie Inc ( ABBV ) - 92,295 shares, 3% of the total portfolio. Rikoon Group, LLC New Purchases: SDY , ACN , ORAN , Added Positions:CVS, DG, DIS, LB, SPY, SHW, ORCL, AAP, AGN, CHL, Reduced Positions:VZ, IMKTA, STO, SAP, AAPL, SHPG, GILD, TOT, XOM, SNY, Sold Out:SNN, IWF, IWD, TGT, ABX, CNQ, SEP, For the details of Riko... | AbbVie Inc ( ABBV ) - 92,295 shares, 3% of the total portfolio. Rikoon Group, LLC New Purchases: SDY , ACN , ORAN , Added Positions:CVS, DG, DIS, LB, SPY, SHW, ORCL, AAP, AGN, CHL, Reduced Positions:VZ, IMKTA, STO, SAP, AAPL, SHPG, GILD, TOT, XOM, SNY, Sold Out:SNN, IWF, IWD, TGT, ABX, CNQ, SEP, For the details of Riko... | AbbVie Inc ( ABBV ) - 92,295 shares, 3% of the total portfolio. Rikoon Group, LLC New Purchases: SDY , ACN , ORAN , Added Positions:CVS, DG, DIS, LB, SPY, SHW, ORCL, AAP, AGN, CHL, Reduced Positions:VZ, IMKTA, STO, SAP, AAPL, SHPG, GILD, TOT, XOM, SNY, Sold Out:SNN, IWF, IWD, TGT, ABX, CNQ, SEP, For the details of Riko... | AbbVie Inc ( ABBV ) - 92,295 shares, 3% of the total portfolio. Rikoon Group, LLC New Purchases: SDY , ACN , ORAN , Added Positions:CVS, DG, DIS, LB, SPY, SHW, ORCL, AAP, AGN, CHL, Reduced Positions:VZ, IMKTA, STO, SAP, AAPL, SHPG, GILD, TOT, XOM, SNY, Sold Out:SNN, IWF, IWD, TGT, ABX, CNQ, SEP, For the details of Riko... |
26,034 | 2017-08-18 00:00:00 UTC | Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada | ABBV | https://www.nasdaq.com/articles/gilead-gild-hcv-drug-vosevi-receives-approval-in-canada-2017-08-18 | null | null | Gilead Sciences, Inc . GILD announced that Health Canada has granted a Notice of Compliance for its single-tablet regimen, Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg), for the treatment of chronic hepatitis C virus (HCV) infection.
Vosevi has been approved for the treatment of HCV infection in adu... | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers' BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV):... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni,... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni,... | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers' BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV):... |
26,035 | 2017-08-17 00:00:00 UTC | Tandem Investment Advisors, Inc. Buys FactSet Research Systems Inc, National Retail Properties ... | ABBV | https://www.nasdaq.com/articles/tandem-investment-advisors-inc-buys-factset-research-systems-inc-national-retail | null | null | Tandem Investment Advisors, Inc.
New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL,
Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD,
Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL,
Sold Out:QCOM,
For the details of Tandem Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocu... | Shares added by 1.78% AbbVie Inc ( ABBV ) - 148,606 shares, 4.28% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the det... | Shares added by 1.78% AbbVie Inc ( ABBV ) - 148,606 shares, 4.28% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the det... | Shares added by 1.78% AbbVie Inc ( ABBV ) - 148,606 shares, 4.28% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the det... | Shares added by 1.78% AbbVie Inc ( ABBV ) - 148,606 shares, 4.28% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the det... |
26,036 | 2017-08-16 00:00:00 UTC | 3 Dividend Healthcare Stocks | ABBV | https://www.nasdaq.com/articles/3-dividend-healthcare-stocks-2017-08-16 | null | null | The rapid aging of the world's population should ensure that demand for healthcare products and services remains on the rise for decades to come. But how can income investors take advantage of the trend? We posed that question to a team of healthcare investors and they suggested to check out AbbVie (NYSE: ABBV) , Medtr... | Long story short, AbbVie needs most of its newly acquired cancer medicines like Imbruvica, Venclexta, and Rova-T, and its emerging anti-inflammatory product candidates such as upadacitinib, to live up to their megablockbuster potential. We posed that question to a team of healthcare investors and they suggested to chec... | A proven winner George Budwell (AbbVie): Despite being dealt a rather difficult hand after being spun off from its parent company Abbott Laboratories in 2013 due to the patent headwinds surrounding the megablockbuster anti-inflammatory medicine Humira, AbbVie has proven to be an outstanding dividend and growth stock. W... | We posed that question to a team of healthcare investors and they suggested to check out AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , and ResMed (NYSE: RMD) . A proven winner George Budwell (AbbVie): Despite being dealt a rather difficult hand after being spun off from its parent company Abbott Laboratories in 2013 du... | We posed that question to a team of healthcare investors and they suggested to check out AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , and ResMed (NYSE: RMD) . A proven winner George Budwell (AbbVie): Despite being dealt a rather difficult hand after being spun off from its parent company Abbott Laboratories in 2013 du... |
26,037 | 2017-08-15 00:00:00 UTC | Stonebridge Capital Advisors LLC Buys Gilead Sciences Inc, Microsoft Corp, SPDR S&P 500, ... | ABBV | https://www.nasdaq.com/articles/stonebridge-capital-advisors-llc-buys-gilead-sciences-inc-microsoft-corp-spdr-sp-500-2017 | null | null | Stonebridge Capital Advisors LLC
New Purchases: SPY , SDY , BHI , HRL, NOBL, AXP, CTSH, ORCL, ZBH,
Added Positions:GILD, MSFT, IVV, BBT, DVY, COP, CVX, XOM, SLB, ACWX,
Reduced Positions:AAPL, HON, MON, BA, WFM, LOW, BRK.B, MDT, WWD, MCHP,
Sold Out:UN, GLW, BHGE, BAX, BMS, OXY,
For the details of Stonebridge Capital Adv... | Shares added by 0.35% AbbVie Inc ( ABBV ) - 112,610 shares, 2.14% of the total portfolio. Stonebridge Capital Advisors LLC New Purchases: SPY , SDY , BHI , HRL, NOBL, AXP, CTSH, ORCL, ZBH, Added Positions:GILD, MSFT, IVV, BBT, DVY, COP, CVX, XOM, SLB, ACWX, Reduced Positions:AAPL, HON, MON, BA, WFM, LOW, BRK.B, MDT, WW... | Shares added by 0.35% AbbVie Inc ( ABBV ) - 112,610 shares, 2.14% of the total portfolio. Stonebridge Capital Advisors LLC New Purchases: SPY , SDY , BHI , HRL, NOBL, AXP, CTSH, ORCL, ZBH, Added Positions:GILD, MSFT, IVV, BBT, DVY, COP, CVX, XOM, SLB, ACWX, Reduced Positions:AAPL, HON, MON, BA, WFM, LOW, BRK.B, MDT, WW... | Shares added by 0.35% AbbVie Inc ( ABBV ) - 112,610 shares, 2.14% of the total portfolio. Stonebridge Capital Advisors LLC New Purchases: SPY , SDY , BHI , HRL, NOBL, AXP, CTSH, ORCL, ZBH, Added Positions:GILD, MSFT, IVV, BBT, DVY, COP, CVX, XOM, SLB, ACWX, Reduced Positions:AAPL, HON, MON, BA, WFM, LOW, BRK.B, MDT, WW... | Shares added by 0.35% AbbVie Inc ( ABBV ) - 112,610 shares, 2.14% of the total portfolio. Stonebridge Capital Advisors LLC New Purchases: SPY , SDY , BHI , HRL, NOBL, AXP, CTSH, ORCL, ZBH, Added Positions:GILD, MSFT, IVV, BBT, DVY, COP, CVX, XOM, SLB, ACWX, Reduced Positions:AAPL, HON, MON, BA, WFM, LOW, BRK.B, MDT, WW... |
26,038 | 2017-08-14 00:00:00 UTC | Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review | ABBV | https://www.nasdaq.com/articles/gilead-gild-nda-for-hiv-combo-regimen-gets-priority-review-2017-08-14 | null | null | Gilead Sciences, Inc . GILD announced that the FDA has granted priority review for the company's New Drug Application (NDA) for an investigational, fixed-dose combination of bictegravir (50mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg) ... | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV)... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni, Sovaldi and ... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni, Sovaldi and ... | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV)... |
26,039 | 2017-08-12 00:00:00 UTC | 3 High-Yield Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-id-buy-right-now-2017-08-12 | null | null | You can find a boatload of dividend stocks with super-high yields. I wouldn't touch many of those stocks with a 10-foot pole, though. Those high yields reflect beaten-down stocks that aren't likely to come back anytime soon in a lot of cases.
However, there are several high-yield dividend stocks that I'd buy right now ... | Here's why AT&T (NYSE: T) , Cisco Systems (NASDAQ: CSCO) , and AbbVie (NYSE: ABBV) stand at the top of that list. AbbVie AbbVie's dividend yield stands at 3.58% -- only slightly behind Cisco. AbbVie uses less than 60% of earnings to cover its dividends. | Here's why AT&T (NYSE: T) , Cisco Systems (NASDAQ: CSCO) , and AbbVie (NYSE: ABBV) stand at the top of that list. AbbVie AbbVie's dividend yield stands at 3.58% -- only slightly behind Cisco. AbbVie uses less than 60% of earnings to cover its dividends. | AbbVie AbbVie's dividend yield stands at 3.58% -- only slightly behind Cisco. Like AT&T, the company is also a Dividend Aristocrat, with a 44-year streak of consecutive dividend increases (including the period in which AbbVie was part of parent Abbott Labs ). Here's why AT&T (NYSE: T) , Cisco Systems (NASDAQ: CSCO) , a... | Earnings growth shouldn't be a problem for AbbVie, either. Here's why AT&T (NYSE: T) , Cisco Systems (NASDAQ: CSCO) , and AbbVie (NYSE: ABBV) stand at the top of that list. AbbVie AbbVie's dividend yield stands at 3.58% -- only slightly behind Cisco. |
26,040 | 2017-08-10 00:00:00 UTC | AbbVie a Top 25 Dividend Giant With 3.56% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-top-25-dividend-giant-356-yield-abbv-2017-08-10 | null | null | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a whopping $6.13B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.56% yield, according to the most recent Dividend Channel''DividendRank'' report. The report noted a strong quart... | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a whopping $6.13B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.56% yield, according to the most recent Dividend Channel''DividendRank'' report. The report noted a strong quart... | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a whopping $6.13B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.56% yield, according to the most recent Dividend Channel''DividendRank'' report. The report noted a strong quart... | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a whopping $6.13B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.56% yield, according to the most recent Dividend Channel''DividendRank'' report. The annualized dividend paid by... | The report noted a strong quarterly dividend history at AbbVie Inc, and favorable long-term multi-year growth rates in key fundamental data points. The annualized dividend paid by AbbVie Inc is $2.56/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/12/2017. AbbVie Inc (Sym... |
26,041 | 2017-08-10 00:00:00 UTC | 3 Value Stocks for Wise Investors | ABBV | https://www.nasdaq.com/articles/3-value-stocks-wise-investors-2017-08-10 | null | null | The S&P 500 's bull run continues to rage on, making it harder and harder for value investors to find good stocks to buy. Thankfully, there are always bargains to be found if you are willing to turn over enough rocks.
So which discounted stocks do we think are worthy of consideration today? We asked posed that question... | We asked posed that question to our investors and they picked Amplify Snack Brands (NYSE: BETR) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . Growth at a reasonable price Brian Feroldi (AbbVie): Most companies that consistently crank out double-digit revenue and earnings growth trade at lofty valuations, but that's ... | We asked posed that question to our investors and they picked Amplify Snack Brands (NYSE: BETR) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . Growth at a reasonable price Brian Feroldi (AbbVie): Most companies that consistently crank out double-digit revenue and earnings growth trade at lofty valuations, but that's ... | We asked posed that question to our investors and they picked Amplify Snack Brands (NYSE: BETR) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . Growth at a reasonable price Brian Feroldi (AbbVie): Most companies that consistently crank out double-digit revenue and earnings growth trade at lofty valuations, but that's ... | We asked posed that question to our investors and they picked Amplify Snack Brands (NYSE: BETR) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . Growth at a reasonable price Brian Feroldi (AbbVie): Most companies that consistently crank out double-digit revenue and earnings growth trade at lofty valuations, but that's ... |
26,042 | 2017-08-09 00:00:00 UTC | Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-q2-earnings-regeneron-kite-more-fibrogen-ipf-data-2017-08-09 | null | null | Regeneron REGN and several mid-and small-cap biotech stocks reported earnings results while companies like Dynavax DVAX and AbbVie ABBV provided regulatory updates.
Recap of the Week's Most Important Stories
A Look at Earnings Results: Regeneron reported a strong quarter with the company surpassing both earnings and re... | Regeneron REGN and several mid-and small-cap biotech stocks reported earnings results while companies like Dynavax DVAX and AbbVie ABBV provided regulatory updates. Among major biotech stocks, Celgene CELG and Vertex VRTX recorded minimal gains while Gilead lost 3.2% reflecting the impact of the approval of AbbVie's ne... | Regeneron REGN and several mid-and small-cap biotech stocks reported earnings results while companies like Dynavax DVAX and AbbVie ABBV provided regulatory updates. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Regener... | AbbVie's New HCV Treatment Gets FDA Nod: AbbVie's 8-week, pan-genotypic, ribavirin-free, once-daily hepatitis C virus (HCV) treatment, Mavyret, gained FDA approval for use in HCV patients without cirrhosis and who are new to treatment. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex ... | Regeneron REGN and several mid-and small-cap biotech stocks reported earnings results while companies like Dynavax DVAX and AbbVie ABBV provided regulatory updates. AbbVie's New HCV Treatment Gets FDA Nod: AbbVie's 8-week, pan-genotypic, ribavirin-free, once-daily hepatitis C virus (HCV) treatment, Mavyret, gained FDA ... |
26,043 | 2017-08-08 00:00:00 UTC | Bellwether Investment Group, LLC Buys Salesforce. ... | ABBV | https://www.nasdaq.com/articles/bellwether-investment-group-llc-buys-salesforce-2017-08-08 | null | null | Bellwether Investment Group, LLC
New Purchases: HIG ,
Added Positions: CRM , BA , FFA, HD, EPD, V, PFE, KO, OAS, AAPL,
Reduced Positions:ORLY, MCD, BRK.B, IWM, CPB, SO, T, TXN, PM, QQQ,
Sold Out:AVT, INTC, KMI, VZ, CMCSA, DD, BDX, FB, FTAI, GLD,
For the details of Bellwether Investment Group, LLC's stock buys and sells... | Shares added by 0.22% AbbVie Inc ( ABBV ) - 10,330 shares, 3.65% of the total portfolio. Bellwether Investment Group, LLC New Purchases: HIG , Added Positions: CRM , BA , FFA, HD, EPD, V, PFE, KO, OAS, AAPL, Reduced Positions:ORLY, MCD, BRK.B, IWM, CPB, SO, T, TXN, PM, QQQ, Sold Out:AVT, INTC, KMI, VZ, CMCSA, DD, BDX, ... | Shares added by 0.22% AbbVie Inc ( ABBV ) - 10,330 shares, 3.65% of the total portfolio. Bellwether Investment Group, LLC New Purchases: HIG , Added Positions: CRM , BA , FFA, HD, EPD, V, PFE, KO, OAS, AAPL, Reduced Positions:ORLY, MCD, BRK.B, IWM, CPB, SO, T, TXN, PM, QQQ, Sold Out:AVT, INTC, KMI, VZ, CMCSA, DD, BDX, ... | Shares added by 0.22% AbbVie Inc ( ABBV ) - 10,330 shares, 3.65% of the total portfolio. Bellwether Investment Group, LLC New Purchases: HIG , Added Positions: CRM , BA , FFA, HD, EPD, V, PFE, KO, OAS, AAPL, Reduced Positions:ORLY, MCD, BRK.B, IWM, CPB, SO, T, TXN, PM, QQQ, Sold Out:AVT, INTC, KMI, VZ, CMCSA, DD, BDX, ... | Shares added by 0.22% AbbVie Inc ( ABBV ) - 10,330 shares, 3.65% of the total portfolio. Added: Salesforce.com Inc (CRM) Bellwether Investment Group, LLC added to the holdings in Salesforce.com Inc by 3196.69%. du Pont de Nemours & Co (DD) Bellwether Investment Group, LLC sold out the holdings in E.I. |
26,044 | 2017-08-08 00:00:00 UTC | Here's Why Coherus Biosciences Rose as Much as 22.2% Today | ABBV | https://www.nasdaq.com/articles/heres-why-coherus-biosciences-rose-much-222-today-2017-08-08 | null | null | What happened
Shares of generic biologics developer Coherus Biosciences (NASDAQ: CHRS) rose over 22% today after the the company announced second-quarter 2017 financial results and the filing of a petition to invalidate certain Amgen (NASDAQ: AMGN) patents pertaining to the manufacture of Enbrel. If the United States P... | Humira biosimilar candidate: Received ruling from U.S. PTO in favor of its petition to invalidate claims of several AbbVie patents. The progress is encouraging, but biosimilars are complex drugs, and innovator drug owners such as Amgen and AbbVie have fought hard to keep their monopolies intact for as long as possible.... | Humira biosimilar candidate: Received ruling from U.S. PTO in favor of its petition to invalidate claims of several AbbVie patents. The progress is encouraging, but biosimilars are complex drugs, and innovator drug owners such as Amgen and AbbVie have fought hard to keep their monopolies intact for as long as possible.... | Humira biosimilar candidate: Received ruling from U.S. PTO in favor of its petition to invalidate claims of several AbbVie patents. The progress is encouraging, but biosimilars are complex drugs, and innovator drug owners such as Amgen and AbbVie have fought hard to keep their monopolies intact for as long as possible.... | Humira biosimilar candidate: Received ruling from U.S. PTO in favor of its petition to invalidate claims of several AbbVie patents. The progress is encouraging, but biosimilars are complex drugs, and innovator drug owners such as Amgen and AbbVie have fought hard to keep their monopolies intact for as long as possible.... |
26,045 | 2017-08-07 00:00:00 UTC | 3 Value Stocks for Retirement | ABBV | https://www.nasdaq.com/articles/3-value-stocks-retirement-2017-08-07 | null | null | When choosing the best stocks for your retirement, it's no time to start playing games. You want to go with the best companies in the business for their respective industries that provide a combination of opportunity and security.
We asked three Motley Fool investors to identify stocks they feel fit the bill, so read o... | We asked three Motley Fool investors to identify stocks they feel fit the bill, so read on to understand why they chose AT&T (NYSE: T) , AbbVie (NYSE: ABBV) , and Iron Mountain (NYSE: IRM) . Checking off all the boxes Keith Speights (AbbVie): One of my favorite value stocks for retirement accounts isn't just a value st... | We asked three Motley Fool investors to identify stocks they feel fit the bill, so read on to understand why they chose AT&T (NYSE: T) , AbbVie (NYSE: ABBV) , and Iron Mountain (NYSE: IRM) . Checking off all the boxes Keith Speights (AbbVie): One of my favorite value stocks for retirement accounts isn't just a value st... | Checking off all the boxes Keith Speights (AbbVie): One of my favorite value stocks for retirement accounts isn't just a value stock. We asked three Motley Fool investors to identify stocks they feel fit the bill, so read on to understand why they chose AT&T (NYSE: T) , AbbVie (NYSE: ABBV) , and Iron Mountain (NYSE: IR... | Checking off all the boxes Keith Speights (AbbVie): One of my favorite value stocks for retirement accounts isn't just a value stock. We asked three Motley Fool investors to identify stocks they feel fit the bill, so read on to understand why they chose AT&T (NYSE: T) , AbbVie (NYSE: ABBV) , and Iron Mountain (NYSE: IR... |
26,046 | 2017-08-07 00:00:00 UTC | What's Behind TG Therapeutics Inc.'s 14.4% Rally in July? | ABBV | https://www.nasdaq.com/articles/whats-behind-tg-therapeutics-incs-144-rally-july-2017-08-07 | null | null | What happened
Shares of TG Therapeutics Inc. (NASDAQ: TGTX) gained 14.4% in July, according to data from S&P Global Market Intelligence , despite a lack of positive announcements. It doesn't take much to move a clinical-stage biotech stocks by double-digit percentages, and I'd wager investors digesting developments tha... | Adding ublituximab to the star blood-cancer therapy from AbbVie and Johnson & Johnson led to a 78% objective response rate, and drove the disease into complete remission for 7% of patients. It doesn't take much to move a clinical-stage biotech stocks by double-digit percentages, and I'd wager investors digesting develo... | Adding ublituximab to the star blood-cancer therapy from AbbVie and Johnson & Johnson led to a 78% objective response rate, and drove the disease into complete remission for 7% of patients. So what In June, TG Therapeutics announced positive results from a pivotal trial with its lead drug candidate plus Imbruvica for t... | Adding ublituximab to the star blood-cancer therapy from AbbVie and Johnson & Johnson led to a 78% objective response rate, and drove the disease into complete remission for 7% of patients. TG Therapeutics also announced impressive results from an early-stage trial testing a three-drug cocktail containing two of its ne... | Adding ublituximab to the star blood-cancer therapy from AbbVie and Johnson & Johnson led to a 78% objective response rate, and drove the disease into complete remission for 7% of patients. So what In June, TG Therapeutics announced positive results from a pivotal trial with its lead drug candidate plus Imbruvica for t... |
26,047 | 2017-08-06 00:00:00 UTC | Weekly Top Insider Buys Highlight for the Week of August 4 | ABBV | https://www.nasdaq.com/articles/weekly-top-insider-buys-highlight-week-august-4-2017-08-06 | null | null | The largest Insider Buys this week were for AbbVie Inc. ( ABBV ), Bristol-Myers Squibb Company ( BMY ), General Motors Co. ( GM ) and Kinder Morgan Inc. ( KMI ).
AbbVie Inc ( ABBV ): Director Edward J. Rapp bought 4,000 shares
Director Edward J. Rapp bought 4,000 shares of AbbVie stock on July 31 at the average price o... | The largest Insider Buys this week were for AbbVie Inc. ( ABBV ), Bristol-Myers Squibb Company ( BMY ), General Motors Co. ( GM ) and Kinder Morgan Inc. ( KMI ). AbbVie Inc ( ABBV ): Director Edward J. Rapp bought 4,000 shares Director Edward J. Rapp bought 4,000 shares of AbbVie stock on July 31 at the average price o... | The largest Insider Buys this week were for AbbVie Inc. ( ABBV ), Bristol-Myers Squibb Company ( BMY ), General Motors Co. ( GM ) and Kinder Morgan Inc. ( KMI ). AbbVie Inc ( ABBV ): Director Edward J. Rapp bought 4,000 shares Director Edward J. Rapp bought 4,000 shares of AbbVie stock on July 31 at the average price o... | The largest Insider Buys this week were for AbbVie Inc. ( ABBV ), Bristol-Myers Squibb Company ( BMY ), General Motors Co. ( GM ) and Kinder Morgan Inc. ( KMI ). AbbVie Inc ( ABBV ): Director Edward J. Rapp bought 4,000 shares Director Edward J. Rapp bought 4,000 shares of AbbVie stock on July 31 at the average price o... | The largest Insider Buys this week were for AbbVie Inc. ( ABBV ), Bristol-Myers Squibb Company ( BMY ), General Motors Co. ( GM ) and Kinder Morgan Inc. ( KMI ). AbbVie Inc. is an American international pharmaceutical company that focuses on discovering, developing, and marketing both biopharmaceuticals and small molec... |
26,048 | 2017-08-06 00:00:00 UTC | The Top Stock You Should Consider for Your IRA | ABBV | https://www.nasdaq.com/articles/top-stock-you-should-consider-your-ira-2017-08-06 | null | null | If you don't have an individual retirement account (IRA), get one. They provide a great option for accumulating retirement savings on a tax-deferred basis. And with a Roth IRA , you won't have to pay taxes on any of your gains along the way.
But how should you invest the money you put into an IRA? For retirement accoun... | AbbVie also recently won European and U.S. approval for its pan-genotypic hepatitis C drug Maviret, which could position it to finally start stealing hep C market share. AbbVie's pipeline candidates include potential blockbusters Elagolix, which targets treatment of endometriosis and uterine fibroids, as well as lung c... | AbbVie's autoimmune disease drug Humira continues to perform admirably. AbbVie's pipeline candidates include potential blockbusters Elagolix, which targets treatment of endometriosis and uterine fibroids, as well as lung cancer drug Rova-T. 3. Here are three key reasons why I think AbbVie (NYSE: ABBV) is the top stock ... | Value With its great dividend and tremendous growth prospects, you might think that AbbVie stock would be priced to perfection. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Here are three key reasons why I think AbbVie (NYSE: ABBV) is the top... | Growth Even better news for investors is that AbbVie's earnings are likely to grow -- a lot. Here are three key reasons why I think AbbVie (NYSE: ABBV) is the top stock you should consider adding to your IRA. All this is very pertinent for AbbVie, because the big biotech pays out a very nice dividend. |
26,049 | 2017-08-05 00:00:00 UTC | Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance? | ABBV | https://www.nasdaq.com/articles/abbvie-about-deliver-blow-gilead-sciences-guidance-2017-08-05 | null | null | After boosting its full-year hepatitis C revenue guidance last month, Gilead Sciences ' (NASDAQ: GILD) share price has been rallying. However, the Food and Drug Administration approved AbbVie' s (NYSE: ABBV) next-generation hepatitis C drug Mavyret this week, and AbbVie has priced it to sell. Could Mavyret deliver a bi... | However, the Food and Drug Administration approved AbbVie' s (NYSE: ABBV) next-generation hepatitis C drug Mavyret this week, and AbbVie has priced it to sell. Johnson & Johnson , Bristol-Myers Squibb , AbbVie, and Merck & Co. spent big money on hepatitis C research, and all of them launched hepatitis C drugs too. AbbV... | However, the Food and Drug Administration approved AbbVie' s (NYSE: ABBV) next-generation hepatitis C drug Mavyret this week, and AbbVie has priced it to sell. Johnson & Johnson , Bristol-Myers Squibb , AbbVie, and Merck & Co. spent big money on hepatitis C research, and all of them launched hepatitis C drugs too. AbbV... | However, the Food and Drug Administration approved AbbVie' s (NYSE: ABBV) next-generation hepatitis C drug Mavyret this week, and AbbVie has priced it to sell. Johnson & Johnson , Bristol-Myers Squibb , AbbVie, and Merck & Co. spent big money on hepatitis C research, and all of them launched hepatitis C drugs too. AbbV... | However, the Food and Drug Administration approved AbbVie' s (NYSE: ABBV) next-generation hepatitis C drug Mavyret this week, and AbbVie has priced it to sell. Johnson & Johnson , Bristol-Myers Squibb , AbbVie, and Merck & Co. spent big money on hepatitis C research, and all of them launched hepatitis C drugs too. AbbV... |
26,050 | 2017-08-04 00:00:00 UTC | Infinity (INFI) Q2 Loss Wider than Expected, View Intact | ABBV | https://www.nasdaq.com/articles/infinity-infi-q2-loss-wider-than-expected-view-intact-2017-08-04 | null | null | Infinity Pharmaceuticals, Inc . INFI reported a loss of 34 cents per share in second-quarter 2017, wider than the Zacks Consensus Estimate loss of 22 cents. The company had reported a loss of 12 cents in the year-ago quarter.
Infinity Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Infinity Pharmaceuticals, Inc... | However, it recorded collaboration revenues of $9.5 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. ABBV . Infinity received a huge setback when AbbVie terminated their collaboration agreement for the development and commercialization of duvelisib. Click to get t... | However, it recorded collaboration revenues of $9.5 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. ABBV . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences,... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. However, it... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. However, it... |
26,051 | 2017-08-03 00:00:00 UTC | 3 Sector Gainers And Losers; 2 Equity Plays Near Buy Zone | ABBV | https://www.nasdaq.com/articles/3-sector-gainers-and-losers-2-equity-plays-near-buy-zone-2017-08-03 | null | null | The Dow Jones industrial average continues to hit highs while the S&P 500 and Nasdaq take a breather.
[ibd-display-video id=2067944 width=50 float=left autostart=true]That could help new buy opportunities to take shape. Two ETFs with big weightings in PayPal ( PYPL ) and Apple ( AAPL ) are poised near buy points.
First... | Top holdings included drugmaker AbbVie ( ABBV ), Kraft Heinz ( KHC ) and PayPal ( PYPL ). AbbVie has advanced 13%. First Trust US Equity Opportunities ( FPX ) is pulling back near its 50-day moving average , after marking a record high last week. | Top holdings included drugmaker AbbVie ( ABBV ), Kraft Heinz ( KHC ) and PayPal ( PYPL ). AbbVie has advanced 13%. [ibdchart symbol="FPX" type="daily" size="threequarter" position="leftchart" /] FPX, which turned 11 in April, has gathered $858.2 million in assets. | Top holdings included drugmaker AbbVie ( ABBV ), Kraft Heinz ( KHC ) and PayPal ( PYPL ). AbbVie has advanced 13%. IShares Edge MSCI U.S. Quality Factor (QUAL), which gained 2% from a June 1 breakout past a 74.39 buy point to a June 19 peak, is testing support at its 50-day line for the second time since the breakout. | Top holdings included drugmaker AbbVie ( ABBV ), Kraft Heinz ( KHC ) and PayPal ( PYPL ). AbbVie has advanced 13%. Two ETFs with big weightings in PayPal ( PYPL ) and Apple ( AAPL ) are poised near buy points. |
26,052 | 2017-08-03 00:00:00 UTC | Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat | ABBV | https://www.nasdaq.com/articles/momenta-mnta-q2-loss-in-line-with-estimates-sales-beat-2017-08-03 | null | null | Momenta Pharmaceuticals Inc.MNTA reported a loss of 50 cents per share in the second quarter of 2017, in line with the Zacks Consensus Estimate. The reported loss was, however, wider than the year-ago loss of 31 cents.
Momenta Pharmaceuticals, Inc. Price and EPS Surprise
Momenta Pharmaceuticals, Inc. Price and EPS Surp... | Currently, Momenta's M923, a biosimilar version of AbbVie, Inc. ABBV Humira, is being evaluated in a phase III study in patients suffering from moderate-to-severe chronic plaque psoriasis. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Momenta's M923, a biosimilar ... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Momenta's M923, a biosimilar ... | Currently, Momenta's M923, a biosimilar version of AbbVie, Inc. ABBV Humira, is being evaluated in a phase III study in patients suffering from moderate-to-severe chronic plaque psoriasis. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta... |
26,053 | 2017-08-03 00:00:00 UTC | Top Buys by Directors: Rapp's $281.8K Bet on ABBV | ABBV | https://www.nasdaq.com/articles/top-buys-directors-rapps-2818k-bet-abbv-2017-08-03 | null | null | The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make mon... | Shares of AbbVie Inc were changing hands at $70.50 at last check, trading down about 0.3% on Thursday. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range is $55.06 per share, with $75.04 as the 52 week high ... | In trading on Thursday, bargain hunters could buy shares of AbbVie Inc (Symbol: ABBV) and achieve a cost basis lower than Rapp, with shares changing hands as low as $70.36 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low ... | In trading on Thursday, bargain hunters could buy shares of AbbVie Inc (Symbol: ABBV) and achieve a cost basis lower than Rapp, with shares changing hands as low as $70.36 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low ... | In trading on Thursday, bargain hunters could buy shares of AbbVie Inc (Symbol: ABBV) and achieve a cost basis lower than Rapp, with shares changing hands as low as $70.36 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low ... |
26,054 | 2017-08-02 00:00:00 UTC | Westchester Capital Management, Inc. Buys Microchip Technology Inc, SPDR S&P Dividend, Ford ... | ABBV | https://www.nasdaq.com/articles/westchester-capital-management-inc-buys-microchip-technology-inc-spdr-sp-dividend-ford | null | null | Westchester Capital Management, Inc.
New Purchases: MCHP , SDY , VZ ,
Added Positions:PFE, AGN, WM, ZBH, MSFT, CVS, SYF, DIS, CSCO, BRK.B,
Reduced Positions:MCD, CAT, GLD,
Sold Out:SPY,
For the details of Westchester Capital Management, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=W... | Shares added by 2.38% AbbVie Inc ( ABBV ) - 147,343 shares, 4.87% of the total portfolio. Westchester Capital Management, Inc. New Purchases: MCHP , SDY , VZ , Added Positions:PFE, AGN, WM, ZBH, MSFT, CVS, SYF, DIS, CSCO, BRK.B, Reduced Positions:MCD, CAT, GLD, Sold Out:SPY, For the details of Westchester Capital Manag... | Shares added by 2.38% AbbVie Inc ( ABBV ) - 147,343 shares, 4.87% of the total portfolio. Westchester Capital Management, Inc. New Purchases: MCHP , SDY , VZ , Added Positions:PFE, AGN, WM, ZBH, MSFT, CVS, SYF, DIS, CSCO, BRK.B, Reduced Positions:MCD, CAT, GLD, Sold Out:SPY, For the details of Westchester Capital Manag... | Shares added by 2.38% AbbVie Inc ( ABBV ) - 147,343 shares, 4.87% of the total portfolio. Westchester Capital Management, Inc. New Purchases: MCHP , SDY , VZ , Added Positions:PFE, AGN, WM, ZBH, MSFT, CVS, SYF, DIS, CSCO, BRK.B, Reduced Positions:MCD, CAT, GLD, Sold Out:SPY, For the details of Westchester Capital Manag... | Shares added by 2.38% AbbVie Inc ( ABBV ) - 147,343 shares, 4.87% of the total portfolio. These are the top 5 holdings of Westchester Capital Management, Inc. Apple Inc ( AAPL ) - 79,397 shares, 5.21% of the total portfolio. Shares added by 3.66% New Purchase: Microchip Technology Inc ( MCHP ) Westchester Capital Manag... |
26,055 | 2017-08-02 00:00:00 UTC | Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-q2-earnings-gilead-celg-more-dynavax-panel-vote-2017-08-02 | null | null | Major biotech stocks like Gilead GILD , Celgene CELG , Alexion, AbbVie ABBV and Vertex VRTX reported second quarter results over the last few days. Companies like Gilead and Amgen AMGN also provided regulatory updates.
Recap of the Week's Most Important Stories
A Look at Q2 Earnings Results: Gilead's results were stron... | Major biotech stocks like Gilead GILD , Celgene CELG , Alexion, AbbVie ABBV and Vertex VRTX reported second quarter results over the last few days. Vertex (Read more: Vertex Q2 Earnings Top on Solid Cystic Fibrosis Sales ) and AbbVie too topped expectations (Read more: AbbVie Tops Q2 Earnings & Revenues, Outlook Intact... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock ... | Major biotech stocks like Gilead GILD , Celgene CELG , Alexion, AbbVie ABBV and Vertex VRTX reported second quarter results over the last few days. Vertex (Read more: Vertex Q2 Earnings Top on Solid Cystic Fibrosis Sales ) and AbbVie too topped expectations (Read more: AbbVie Tops Q2 Earnings & Revenues, Outlook Intact... |
26,056 | 2017-08-01 00:00:00 UTC | 3 Growth Stocks for the Long Term | ABBV | https://www.nasdaq.com/articles/3-growth-stocks-long-term-2017-08-01 | null | null | Growth stocks are key components of any well-rounded portfolio. However, it's not always easy to identify stocks that can produce respectable returns on capital over long periods of time.
With this theme in mind, we asked three of our Foolish investors which growth stocks they think might be worth buying and holding ri... | They suggested AbbVie (NYSE: ABBV) , Take-Two Interactive (NASDAQ: TTWO) , and Iridium Communications (NASDAQ: IRDM) . A super-charged growth stock George Budwell (AbbVie): Despite the headwinds surrounding the legal defense for top-selling anti-inflammatory drug Humira, AbbVie continues to deliver industry-leading lev... | They suggested AbbVie (NYSE: ABBV) , Take-Two Interactive (NASDAQ: TTWO) , and Iridium Communications (NASDAQ: IRDM) . A super-charged growth stock George Budwell (AbbVie): Despite the headwinds surrounding the legal defense for top-selling anti-inflammatory drug Humira, AbbVie continues to deliver industry-leading lev... | A super-charged growth stock George Budwell (AbbVie): Despite the headwinds surrounding the legal defense for top-selling anti-inflammatory drug Humira, AbbVie continues to deliver industry-leading levels of growth, and this trend should be sustainable for the foreseeable future. They suggested AbbVie (NYSE: ABBV) , Ta... | They suggested AbbVie (NYSE: ABBV) , Take-Two Interactive (NASDAQ: TTWO) , and Iridium Communications (NASDAQ: IRDM) . A super-charged growth stock George Budwell (AbbVie): Despite the headwinds surrounding the legal defense for top-selling anti-inflammatory drug Humira, AbbVie continues to deliver industry-leading lev... |
26,057 | 2017-08-01 00:00:00 UTC | Validea Joel Greenblatt Strategy Daily Upgrade Report - 8/1/2017 | ABBV | https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-812017-2017-08-01 | null | null | The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.
ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating accor... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Met... | Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. |
26,058 | 2017-08-01 00:00:00 UTC | Key FDA Events to Watch Out for in Aug 2017 | ABBV | https://www.nasdaq.com/articles/key-fda-events-watch-out-aug-2017-2017-08-01 | null | null | The FDA, which approved 22 treatments last year, has given its approval to 26 drugs so far in 2017 including 3 in July. Key approvals this year include Gilead's Vosevi (hepatitis C virus), Puma's Nerlynx (to reduce the risk of breast cancer returning), J&J's Tremfya (moderate-to-severe plaque psoriasis), Regeneron/Sano... | Will FDA Follow in EU's Path and Give the Green Signal to AbbVie's Maviret? AbbVie ABBV also has an important regulatory event coming up with the FDA expected to respond on the approval status of the company's latest hepatitis C virus (HCV) offering this month. Maviret represents blockbuster potential and could help Ab... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Dynavax Technologi... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Dynavax Technologi... | Will FDA Follow in EU's Path and Give the Green Signal to AbbVie's Maviret? AbbVie ABBV also has an important regulatory event coming up with the FDA expected to respond on the approval status of the company's latest hepatitis C virus (HCV) offering this month. Maviret represents blockbuster potential and could help Ab... |
26,059 | 2017-07-31 00:00:00 UTC | 7 Explosive Healthcare Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/7-explosive-healthcare-stocks-to-buy-now-2017-07-31 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The healthcare sector, along with its many sub-industries, has taken a leadership role in the market again in 2017. The strength in the sector can be attributed to a few things.
First, the sector is benefiting from the lack of volatility that had been tied ... | Explosive Healthcare Stocks to Buy: AbbVie Inc (ABBV) Click to Enlarge Dipping into the biotech stocks, AbbVie Inc (NYSE: ABBV ) is a standout as the company has been able to maintain some low-volatility leadership. AbbVie is trading 11% higher for the year, as ABBV stock trades strongly in a leadership role since the ... | Explosive Healthcare Stocks to Buy: AbbVie Inc (ABBV) Click to Enlarge Dipping into the biotech stocks, AbbVie Inc (NYSE: ABBV ) is a standout as the company has been able to maintain some low-volatility leadership. AbbVie is trading 11% higher for the year, as ABBV stock trades strongly in a leadership role since the ... | Explosive Healthcare Stocks to Buy: AbbVie Inc (ABBV) Click to Enlarge Dipping into the biotech stocks, AbbVie Inc (NYSE: ABBV ) is a standout as the company has been able to maintain some low-volatility leadership. AbbVie is trading 11% higher for the year, as ABBV stock trades strongly in a leadership role since the ... | Explosive Healthcare Stocks to Buy: AbbVie Inc (ABBV) Click to Enlarge Dipping into the biotech stocks, AbbVie Inc (NYSE: ABBV ) is a standout as the company has been able to maintain some low-volatility leadership. AbbVie is trading 11% higher for the year, as ABBV stock trades strongly in a leadership role since the ... |
26,060 | 2017-07-31 00:00:00 UTC | 5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You | ABBV | https://www.nasdaq.com/articles/5-things-gilead-sciences-q2-earnings-numbers-didnt-tell-you-2017-07-31 | null | null | The numbers didn't lie: Gilead Sciences (NASDAQ: GILD) posted pretty good second-quarter results . While revenue and earnings fell compared to the prior-year period, the big biotech still managed to beat expectations thanks to strong HIV drug sales and a better-than-expected performance from its hepatitis C virus (HCV)... | AbbVie (NYSE: ABBV) announced European approval for its single-pill for treating all genotypes of HCV on July 28. The drug, branded as Maviret, is also under priority review in the U.S. AbbVie's previous HCV drug, Viekira, didn't make as big of a splash as the company would have liked. AbbVie's level of success with Ma... | AbbVie (NYSE: ABBV) announced European approval for its single-pill for treating all genotypes of HCV on July 28. The drug, branded as Maviret, is also under priority review in the U.S. AbbVie's previous HCV drug, Viekira, didn't make as big of a splash as the company would have liked. AbbVie's level of success with Ma... | AbbVie's level of success with Maviret is important for Gilead, since Epclusa has been the main bright spot amid the dark overall picture for Gilead's HCV franchise. AbbVie (NYSE: ABBV) announced European approval for its single-pill for treating all genotypes of HCV on July 28. The drug, branded as Maviret, is also un... | AbbVie (NYSE: ABBV) announced European approval for its single-pill for treating all genotypes of HCV on July 28. The drug, branded as Maviret, is also under priority review in the U.S. AbbVie's previous HCV drug, Viekira, didn't make as big of a splash as the company would have liked. AbbVie's level of success with Ma... |
26,061 | 2017-07-28 00:00:00 UTC | Dow Hits Another Record, NASDAQ Hits a Wall | ABBV | https://www.nasdaq.com/articles/dow-hits-another-record-nasdaq-hits-wall-2017-07-28 | null | null | It appeared that the NASDAQ was well on its way to an amazing 14th gain in 15 days on Thursday...and then the bottom dropped out. All of a sudden, the index plunged by approximately 1.5% at its lowest point. It was able to make up a good amount of that loss by the closing bell, but was still off by 0.63% today to 6382.... | • AbbVie (ABBV): This is a volatile stock that reports earnings tomorrow. Kevin believes the move is way overdone, but he sees an opportunity now that the plunge has decimated the short side of yesterday's bull call spread. If you would like to follow our Buy and Sell signals in real time, we've made a special arrangem... | • AbbVie (ABBV): This is a volatile stock that reports earnings tomorrow. Look at all the moves in the highlights section below: Today's Portfolio Highlights: Zacks Counterstrike: In early May, Craft Brew Alliance (BREW) announced a positive surprise of 50%, and now its getting prepared to report again next week. So he... | • AbbVie (ABBV): This is a volatile stock that reports earnings tomorrow. Look at all the moves in the highlights section below: Today's Portfolio Highlights: Zacks Counterstrike: In early May, Craft Brew Alliance (BREW) announced a positive surprise of 50%, and now its getting prepared to report again next week. So he... | • AbbVie (ABBV): This is a volatile stock that reports earnings tomorrow. The editors aren't alarmed. And as you'll see in the highlights section below, Dave said in Momentum Trader that this drop provides one of the better buying opportunities in a while. |
26,062 | 2017-07-28 00:00:00 UTC | Health Care Sector Update for 07/28/2017: ENTA, ABBV, CYTR, ATNM | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-07282017-enta-abbv-cytr-atnm-2017-07-28 | null | null | Top Health Care Stocks
JNJ +0.84%
PFE +0.47%
ABT -0.91%
MRK +0.72%
AMGN +1.52%
Health care stocks continued to add to their prior gains on Friday, with the NYSE Health Care Index rising more than 0.3% while shares of health care companies in the S&P 500 were up almost 0.6% as a group.
In company news, Enanta Pharmaceut... | In company news, Enanta Pharmaceuticals ( ENTA ) was narrowly lower in late Friday trading, with shares of the early-stage biotech company retreating from an initial bounce to within 10 cent of its 52-week high of $38.40 a share after the company said corporate partner AbbVie ( ABBV ) today received marketing authoriza... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In company news, Enanta Pharmaceuticals ( ENTA ) was narrowly lower in late Friday trading, with shares of the early-stage biotech company retreating from an initial bounce to within 10 ... | In company news, Enanta Pharmaceuticals ( ENTA ) was narrowly lower in late Friday trading, with shares of the early-stage biotech company retreating from an initial bounce to within 10 cent of its 52-week high of $38.40 a share after the company said corporate partner AbbVie ( ABBV ) today received marketing authoriza... | AbbVie shares also were lower this afternoon, falling more than 2% to around $70 apiece shortly before the closing bell. In company news, Enanta Pharmaceuticals ( ENTA ) was narrowly lower in late Friday trading, with shares of the early-stage biotech company retreating from an initial bounce to within 10 cent of its 5... |
26,063 | 2017-07-28 00:00:00 UTC | AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-tops-q2-earnings-revenues-outlook-intact-2017-07-28 | null | null | AbbVie Inc. ABBV reported better-than-expected results in the second quarter of 2017. The company surpassed both earnings and sales expectations.
In the year so far, AbbVie's shares have rallied 11.8%, thus favorably comparing with the industry 's increase of 9.9%.
The company posted revenues of $6.94 billion in the re... | AbbVie Inc. ABBV reported better-than-expected results in the second quarter of 2017. In the year so far, AbbVie's shares have rallied 11.8%, thus favorably comparing with the industry 's increase of 9.9%. AbbVie recorded $98 million of international profit-sharing with Johnson & Johnson JNJ . | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson &... | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson &... | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie Inc. ABBV reported better-than-expected results in the second quarter of 2017. In the year so far, AbbVie's shares have rallied 1... |
26,064 | 2017-07-28 00:00:00 UTC | AbbVie (ABBV) Tops Q2 Earnings and Revenue | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-tops-q2-earnings-and-revenue-2017-07-28 | null | null | North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, acti... | North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. AbbVie's performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. AbbVie's flagship product Humira is a... | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to... | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to... | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below: ... |
26,065 | 2017-07-28 00:00:00 UTC | Opus Investment Management Inc Buys Vanguard High Dividend Yield ETF - DNQ, Schwab US Dividend ... | ABBV | https://www.nasdaq.com/articles/opus-investment-management-inc-buys-vanguard-high-dividend-yield-etf-dnq-schwab-us | null | null | Opus Investment Management Inc
New Purchases: OKE , COST , XOM , FITB, USB, OGE,
Added Positions:VYM, SCHD, VEA, WFC, BBT, IP, AMGN, INTC, GXP, GIS,
Reduced Positions:SO, ETR, VVC, WMT, DOW, PG, PCG, GE, AEP, POR,
Sold Out:DVY,
For the details of OPUS INVESTMENT MANAGEMENT INC's stock buys and sells, go to http://www.g... | Shares added by 70.14% AbbVie Inc ( ABBV ) - 96,700 shares, 1.22% of the total portfolio. Opus Investment Management Inc New Purchases: OKE , COST , XOM , FITB, USB, OGE, Added Positions:VYM, SCHD, VEA, WFC, BBT, IP, AMGN, INTC, GXP, GIS, Reduced Positions:SO, ETR, VVC, WMT, DOW, PG, PCG, GE, AEP, POR, Sold Out:DVY, Fo... | Shares added by 70.14% AbbVie Inc ( ABBV ) - 96,700 shares, 1.22% of the total portfolio. Opus Investment Management Inc New Purchases: OKE , COST , XOM , FITB, USB, OGE, Added Positions:VYM, SCHD, VEA, WFC, BBT, IP, AMGN, INTC, GXP, GIS, Reduced Positions:SO, ETR, VVC, WMT, DOW, PG, PCG, GE, AEP, POR, Sold Out:DVY, Fo... | Shares added by 70.14% AbbVie Inc ( ABBV ) - 96,700 shares, 1.22% of the total portfolio. Opus Investment Management Inc New Purchases: OKE , COST , XOM , FITB, USB, OGE, Added Positions:VYM, SCHD, VEA, WFC, BBT, IP, AMGN, INTC, GXP, GIS, Reduced Positions:SO, ETR, VVC, WMT, DOW, PG, PCG, GE, AEP, POR, Sold Out:DVY, Fo... | Shares added by 70.14% AbbVie Inc ( ABBV ) - 96,700 shares, 1.22% of the total portfolio. Opus Investment Management Inc New Purchases: OKE , COST , XOM , FITB, USB, OGE, Added Positions:VYM, SCHD, VEA, WFC, BBT, IP, AMGN, INTC, GXP, GIS, Reduced Positions:SO, ETR, VVC, WMT, DOW, PG, PCG, GE, AEP, POR, Sold Out:DVY, Fo... |
26,066 | 2017-07-28 00:00:00 UTC | AbbVie Inc (ABBV) Q2 Beat Fueled by Best World’s Best-Selling Drug | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-q2-beat-fueled-by-best-worlds-best-selling-drug-2017-07-28 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) reported today that Q2 earnings rose to $1.92 billion, or $1.42 per share versus $1.61 billion, or 98 cents a share, last year. ABBV stock was little changed at 9:22 am ahead of the market open.
Source: Black Stripe via Wikimedia (M... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) reported today that Q2 earnings rose to $1.92 billion, or $1.42 per share versus $1.61 billion, or 98 cents a share, last year. Source: Black Stripe via Wikimedia (Modified) The Chicago-based biopharmaceutical company beat analysts ... | Source: Black Stripe via Wikimedia (Modified) The Chicago-based biopharmaceutical company beat analysts estimates of $1.40 per share AbbVie's net revenue rose 7.6% to $6.94 billion; Analysts average forecast was $6.93 billion ABBV said sales of Humira increased 13.7% to $4.72 billion in the quarter ended June 30; the r... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) reported today that Q2 earnings rose to $1.92 billion, or $1.42 per share versus $1.61 billion, or 98 cents a share, last year. Source: Black Stripe via Wikimedia (Modified) The Chicago-based biopharmaceutical company beat analysts ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) reported today that Q2 earnings rose to $1.92 billion, or $1.42 per share versus $1.61 billion, or 98 cents a share, last year. ABBV stock was little changed at 9:22 am ahead of the market open. Source: Black Stripe via Wikimedia (M... |
26,067 | 2017-07-28 00:00:00 UTC | 4 Drug Stocks in Focus this World Hepatitis Day | ABBV | https://www.nasdaq.com/articles/4-drug-stocks-focus-world-hepatitis-day-2017-07-28 | null | null | Every year on Jul 28, World Hepatitis Day (WHD) is observed to raise awareness about viral hepatitis, one of the leading causes of death across the world.
According to the World Health Organization (WHO), viral hepatitis caused 1.34 million deaths across the world in 2015 and many people remain unaware of being infecte... | AbbVie Inc. ABBV also has a major presence in the HCV market. AbbVie is currently seeking approval for Maviret, an investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). Maviret represents blockbuster potential and could help AbbVie gain major market share once approved and launched. | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Enanta Pharmaceuticals, Inc. (ENTA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV als... | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Enanta Pharmaceuticals, Inc. (ENTA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV als... | Maviret represents blockbuster potential and could help AbbVie gain major market share once approved and launched. AbbVie Inc. ABBV also has a major presence in the HCV market. AbbVie is currently seeking approval for Maviret, an investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). |
26,068 | 2017-07-28 00:00:00 UTC | Earnings Reaction History: AbbVie Inc., 45.5% Follow-Through Indicator, 3.1% Sensitive | ABBV | https://www.nasdaq.com/articles/earnings-reaction-history-abbvie-inc-455-follow-through-indicator-31-sensitive-2017-07-28 | null | null | Expected Earnings Release: 07/28/2017, Premarket
Avg. Extended-Hours Dollar Volume: $8,562,832
AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings an... | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 2.2% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of t... | Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to... | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 2.2% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of t... | Extended-Hours Dollar Volume: $8,562,832 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value ... |
26,069 | 2017-07-27 00:00:00 UTC | Friday's Earnings Reports To Watch: XOM, CVX, MRK, ABBV | ABBV | https://www.nasdaq.com/articles/fridays-earnings-reports-watch-xom-cvx-mrk-abbv-2017-07-27 | null | null | Earnings season is upon us, which means that countless publicly traded companies continue to release quarterly earnings reports, updating investors on the company's financial results and providing insight on how the economy has performed throughout the past quarter.
However, the insane amount of press releases during e... | The fact that AbbVie has defeated its earnings projections in each of its past thirteen operational quarters dating back to 2014, coupled with its adequate Zacks Rank #3 (Hold), should instill some confidence in investors as we approach the report. AbbVie Inc. (ABBV) - Friday, July 28 - Before Market Open AbbVie is a g... | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. (ABBV) - Friday, ... | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. (ABBV) - Friday, ... | AbbVie Inc. (ABBV) - Friday, July 28 - Before Market Open AbbVie is a global, research-based biopharmaceutical company which focuses developing and marketing advanced therapies that address some of the world's most complex diseases. According to the Zacks Consensus Estimates, AbbVie is projected to report revenues of $... |
26,070 | 2017-07-27 00:00:00 UTC | Pre-Market Earnings Report for July 28, 2017 : XOM, CVX, MRK, ABBV, TRP, LYB, HCN, BEN, WY, IMO, AAL, VTR | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-july-28-2017-xom-cvx-mrk-abbv-trp-lyb-hcn-ben-wy-imo-aal-vtr | null | null | The following companies are expected to report earnings prior to market open on 07/28/2017. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation ( XOM ) is reporting for the quarter ending June 30, 2017. The oil company's consensus earnings per share forecast from the 9 ana... | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2017. In the past year ABBV has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 13.15 vs. an industry ratio of 17.30. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2017. In the past year ABBV has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 13.15 vs. an industry ratio of 17.30. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2017. In the past year ABBV has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 13.15 vs. an industry ratio of 17.30. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2017. In the past year ABBV has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABBV is 13.15 vs. an industry ratio of 17.30. |
26,071 | 2017-07-27 00:00:00 UTC | Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales | ABBV | https://www.nasdaq.com/articles/vertex-vrtx-q2-earnings-top-on-solid-cystic-fibrosis-sales-2017-07-27 | null | null | Vertex Pharmaceuticals IncorporatedVRTX reported second-quarter 2017 earnings per share of 10 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 6 cents. Notably, the company had posted a loss of 1 cent in the year-ago quarter. Strong product revenues led to hig... | Belgian company, Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Concert... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Concert Pharmaceuticals, Inc. (CNCE): Free Stock Analysis Report To read this article on Zacks.com click here. Belgian compa... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Concert Pharmaceuticals, Inc. (CNCE): Free Stock Analysis Report To read this article on Zacks.com click here. Belgian compa... | Belgian company, Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Concert... |
26,072 | 2017-07-27 00:00:00 UTC | Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up | ABBV | https://www.nasdaq.com/articles/gilead-gild-tops-q2-earnings-revenue-estimates-stock-up-2017-07-27 | null | null | Gilead Sciences, Inc.'sGILD reported results for the second quarter wherein both earnings and revenues surpassed expectations.
Second-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.51 per share beat the Zacks Consensus Estimate of $2.11. However, earnings were below the year-ago... | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's, Inc. ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead S... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Soval... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Soval... | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's, Inc. ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead S... |
26,073 | 2017-07-27 00:00:00 UTC | Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK | ABBV | https://www.nasdaq.com/articles/pharma-stocks-to-watch-for-earnings-on-jul-28%3A-abbv-mrk-2017-07-27 | null | null | The second-quarter reporting cycle is in full swing. The quarter, undoubtedly, is off to a strong start.
As of Jul 26, 2017, 171 S&P 500 members, accounting for 44.1% of the index's total market capitalization, reported results, according to Earnings Preview .
Total earnings for these 171 index members were up 8.8% fro... | AbbVie Inc.ABBV AbbVie, which is scheduled to release earnings before market opens, had delivered a positive earnings surprise of 1.59% last quarter. AbbVie's earnings performance has been mixed with earnings beating expectations in two of the last four quarters and meeting the same in the remaining two, resulting in a... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Amgen ... | AbbVie's earnings performance has been mixed with earnings beating expectations in two of the last four quarters and meeting the same in the remaining two, resulting in an average positive surprise of 1.65%. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline PLC (GSK):... | AbbVie Inc.ABBV AbbVie, which is scheduled to release earnings before market opens, had delivered a positive earnings surprise of 1.59% last quarter. AbbVie's earnings performance has been mixed with earnings beating expectations in two of the last four quarters and meeting the same in the remaining two, resulting in a... |
26,074 | 2017-07-26 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-upside-analyst-targets-2017-07-26 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow ... | Get the latest Zacks research report on ABBV - FREE Get the latest Zacks research report on APD - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With all of this demand for shares, divide... | Get the latest Zacks research report on ABBV - FREE Get the latest Zacks research report on APD - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The recent share price, average analyst 12... | Get the latest Zacks research report on ABBV - FREE Get the latest Zacks research report on APD - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked thr... | Get the latest Zacks research report on ABBV - FREE Get the latest Zacks research report on APD - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked thr... |
26,075 | 2017-07-26 00:00:00 UTC | Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense | ABBV | https://www.nasdaq.com/articles/gilead-sciences-has-3-available-options-only-1-makes-sense-2017-07-26 | null | null | Gilead Sciences (NASDAQ: GILD) is nearing a crossroads of sorts. In short, AbbVie 's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a significant competitive threat to the biotech's struggling hep C franchise moving forward.
That's seriously bad news from a value... | In short, AbbVie 's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a significant competitive threat to the biotech's struggling hep C franchise moving forward. Even if the biotech can accelerate the development of its more attractive clinical assets such as its a... | In short, AbbVie 's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a significant competitive threat to the biotech's struggling hep C franchise moving forward. Even if the biotech can accelerate the development of its more attractive clinical assets such as its a... | Even if the biotech can accelerate the development of its more attractive clinical assets such as its anti-inflammatory drug filgotinib, it simply won't be enough to head off the entry of AbbVie's latest hep C therapy -- or counteract the other negative headwinds that are literally crushing its hep C franchise right no... | In short, AbbVie 's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a significant competitive threat to the biotech's struggling hep C franchise moving forward. Even if the biotech can accelerate the development of its more attractive clinical assets such as its a... |
26,076 | 2017-07-25 00:00:00 UTC | Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up | ABBV | https://www.nasdaq.com/articles/biogen-biib-tops-q2-earnings-sales-spinraza-sales-up-2017-07-25 | null | null | Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, surpassed expectations both for earnings and sales in the second quarter of 2017. The drugmaker also raised its revenue guidance for 2017 as sales of its newest drug Spinraza (spinal muscular atrophy) witnessed faster-than-expected adoption in t... | Zinbryta, launched in collaboration with AbbVie Inc. ABBV in August last year, contributed $16 million to revenues in the second quarter compared with $11 million in first-quarter 2017. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta, launched in collaboration with AbbVie Inc.... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta, launched in collaboration with AbbVie Inc.... | Zinbryta, launched in collaboration with AbbVie Inc. ABBV in August last year, contributed $16 million to revenues in the second quarter compared with $11 million in first-quarter 2017. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen... |
26,077 | 2017-07-25 00:00:00 UTC | 7 All-Weather Stocks to Buy for the Next 30 Years | ABBV | https://www.nasdaq.com/articles/7-all-weather-stocks-to-buy-for-the-next-30-years-2017-07-25 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Unless you are truly investing for the long-term - and by that, I mean 10 years at a minimum - you expose yourself to a much higher degree of risk. That's why the best stocks to buy if you're a conservative investor are those that are durable, so you can ho... | All-Weather Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Dividend: 3.5% AbbVie Inc (NYSE: ABBV ) was once a piece of Abbott Laboratories (NYSE: ABT ), which completed the spinoff of the research-based pharma outlet that's home to well-known drugs such as Humira and Trico... | All-Weather Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Dividend: 3.5% AbbVie Inc (NYSE: ABBV ) was once a piece of Abbott Laboratories (NYSE: ABT ), which completed the spinoff of the research-based pharma outlet that's home to well-known drugs such as Humira and Trico... | All-Weather Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Dividend: 3.5% AbbVie Inc (NYSE: ABBV ) was once a piece of Abbott Laboratories (NYSE: ABT ), which completed the spinoff of the research-based pharma outlet that's home to well-known drugs such as Humira and Trico... | All-Weather Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Dividend: 3.5% AbbVie Inc (NYSE: ABBV ) was once a piece of Abbott Laboratories (NYSE: ABT ), which completed the spinoff of the research-based pharma outlet that's home to well-known drugs such as Humira and Trico... |
26,078 | 2017-07-24 00:00:00 UTC | Noteworthy ETF Inflows: VYM, PFE, MMM, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows-vym-pfe-mmm-abbv-2017-07-24 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $63.6 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 234,750,... | Among the largest underlying components of VYM, in trading today Pfizer Inc (Symbol: PFE) is down about 0.7%, 3M Co (Symbol: MMM) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.7%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance ... | Among the largest underlying components of VYM, in trading today Pfizer Inc (Symbol: PFE) is down about 0.7%, 3M Co (Symbol: MMM) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.7%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price performance ... | Among the largest underlying components of VYM, in trading today Pfizer Inc (Symbol: PFE) is down about 0.7%, 3M Co (Symbol: MMM) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one s... | Among the largest underlying components of VYM, in trading today Pfizer Inc (Symbol: PFE) is down about 0.7%, 3M Co (Symbol: MMM) is down about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one s... |
26,079 | 2017-07-24 00:00:00 UTC | Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs | ABBV | https://www.nasdaq.com/articles/surprise-store-healthcare-q2-buy-top-ranked-etfs-2017-07-24 | null | null | Despite the hurdles in Trump's plans to repeal and replace Obamacare, healthcare is the second best performing sector this year lagging technology. The optimism comes especially from encouraging industry trends and hopes of a favorable policy environment.
The Trump administration plans to focus on easing regulatory hur... | The trend is likely to continue heading into the Q2 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb BMY are lined up to report this week and in the next. Amgen Inc. Price, Consensus and EPS Surprise Amgen Inc. Price, Consensus and ... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research R... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research R... | Amgen Inc. Price, Consensus and EPS Surprise Amgen Inc. Price, Consensus and EPS Surprise | Amgen Inc. Quote AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.71%, indicating less chance of beating estimates this quarter. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pf... |
26,080 | 2017-07-24 00:00:00 UTC | Why Reata Pharmaceuticals Is Rallying 17.5% Today | ABBV | https://www.nasdaq.com/articles/why-reata-pharmaceuticals-rallying-175-today-2017-07-24 | null | null | What happened
Reata Pharmaceuticals (NASDAQ: RETA) shares were surging 17.5% higher at 3 p.m. EST today, after the company reported that its experimental drug bardoxolone improved kidney function in patients with Alport syndrome.
So what
Alport syndrome is a rare genetic disease that increases the reabsorption of prote... | At the time, the news was a big blow to collaboration partner AbbVie Inc. (NYSE: ABBV) , which had spent hundreds of millions of dollars to get ex-U.S. rights to the drug back in 2010. When it nabbed those rights, AbbVie also invested $300 million in Reata Pharmaceuticals. Currently, AbbVie isn't participating in devel... | At the time, the news was a big blow to collaboration partner AbbVie Inc. (NYSE: ABBV) , which had spent hundreds of millions of dollars to get ex-U.S. rights to the drug back in 2010. When it nabbed those rights, AbbVie also invested $300 million in Reata Pharmaceuticals. Currently, AbbVie isn't participating in devel... | At the time, the news was a big blow to collaboration partner AbbVie Inc. (NYSE: ABBV) , which had spent hundreds of millions of dollars to get ex-U.S. rights to the drug back in 2010. When it nabbed those rights, AbbVie also invested $300 million in Reata Pharmaceuticals. Currently, AbbVie isn't participating in devel... | At the time, the news was a big blow to collaboration partner AbbVie Inc. (NYSE: ABBV) , which had spent hundreds of millions of dollars to get ex-U.S. rights to the drug back in 2010. When it nabbed those rights, AbbVie also invested $300 million in Reata Pharmaceuticals. Currently, AbbVie isn't participating in devel... |
26,081 | 2017-07-24 00:00:00 UTC | Better Buy: Johnson & Johnson vs. AbbVie | ABBV | https://www.nasdaq.com/articles/better-buy-johnson-johnson-vs-abbvie-2017-07-24 | null | null | It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's despite revenue headwinds for J&J and strong sales growth for AbbVie.
Which of these two stocks is the better buy right... | Winner: AbbVie. Thanks to expectations of sustained momentum for Humira and Imbruvica and these new products potentially on the way, Wall Street estimated AbbVie will grow earnings by more than 14% annually over the next five years. And if you count the period where AbbVie was part of its parent Abbott Labs, the compan... | Winner: AbbVie. It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. And that's despite revenue headwinds for J&J and strong sales growth for AbbVie. | Winner: AbbVie. It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. Here's how Johnson & Johnson and AbbVie compare. | Winner: AbbVie. It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. And that's despite revenue headwinds for J&J and strong sales growth for AbbVie. |
26,082 | 2017-07-23 00:00:00 UTC | These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet | ABBV | https://www.nasdaq.com/articles/these-5-drugs-could-be-worth-45-billion-and-theyre-not-even-market-yet-2017-07-23 | null | null | $45 billion for five experimental drugs.
That's how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now. The firm calculated the net present value (the current value of potential future sales) of all the experimental drugs in biopharmaceutical companies' pipe... | AbbVie's management highlights Rova-T as one of the top assets in the biotech's pipeline and is looking to expand the drug's opportunities through combination studies with immuno-oncology therapies. Biogen (NASDAQ: BIIB) , Johnson & Johnson (NYSE: JNJ) , Eli Lilly (NYSE: LLY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ... | Biogen (NASDAQ: BIIB) , Johnson & Johnson (NYSE: JNJ) , Eli Lilly (NYSE: LLY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) can each claim a pipeline candidate in the top five. Rova-T Rova-T is one of several late-stage cancer drugs in AbbVie's pipeline. AbbVie scooped up Rova-T last year with its buyout of Stemce... | Biogen (NASDAQ: BIIB) , Johnson & Johnson (NYSE: JNJ) , Eli Lilly (NYSE: LLY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) can each claim a pipeline candidate in the top five. Rova-T Rova-T is one of several late-stage cancer drugs in AbbVie's pipeline. AbbVie scooped up Rova-T last year with its buyout of Stemce... | Biogen (NASDAQ: BIIB) , Johnson & Johnson (NYSE: JNJ) , Eli Lilly (NYSE: LLY) , AbbVie (NYSE: ABBV) , and Celgene (NASDAQ: CELG) can each claim a pipeline candidate in the top five. Rova-T Rova-T is one of several late-stage cancer drugs in AbbVie's pipeline. AbbVie scooped up Rova-T last year with its buyout of Stemce... |
26,083 | 2017-07-22 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-johnson-johnson-2017-07-22 | null | null | U.S.-based pharmaceutical companies are enjoying a much friendlier business environment under President Trump than his predecessor. President Trump, after all, has backed away from the repeated calls for hard caps on prescription drug prices, and his administration continues to push for corporate tax reform that could ... | Now that AbbVie no longer has to seriously worry about a hard cap on Humira's ever-growing price tag, and the possibility of deleveraging its balance sheet following corporate tax reform in the U.S. remains in play, this drugmaker's best days may indeed be yet to come. The dividend aristocrats AbbVie (NYSE: ABBV) and J... | The dividend aristocrats AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) appear to be especially well-positioned to benefit from Trump's overtly pro-business stance because of their reliance on high-priced specialty medicines for growth and their considerable overseas cash reserves. The net result is that AbbVie ... | The dividend aristocrats AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) appear to be especially well-positioned to benefit from Trump's overtly pro-business stance because of their reliance on high-priced specialty medicines for growth and their considerable overseas cash reserves. The net result is that AbbVie ... | AbbVie: Is the best yet to come? The net result is that AbbVie is forecast by industry experts, such as EvaluatePharma, to push beyond Humira's patent headwinds to remain a top dividend growth stock heading into 2022. The dividend aristocrats AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) appear to be especially... |
26,084 | 2017-07-21 00:00:00 UTC | AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store? | ABBV | https://www.nasdaq.com/articles/abbvie-incs.-abbv-q2-earnings%3A-disappointment-in-store-2017-07-21 | null | null | AbbVie Inc.ABBV is scheduled to release second-quarter 2017 earnings, before the opening bell on Jul 28.
AbbVie's shares have rallied 18.2% so far this year, while the industry has recorded an increase of 13.2%.
Last quarter, the company delivered a positive surprise of 1.59%. We note that AbbVie's earnings history is ... | AbbVie Inc.ABBV is scheduled to release second-quarter 2017 earnings, before the opening bell on Jul 28. AbbVie's shares have rallied 18.2% so far this year, while the industry has recorded an increase of 13.2%. We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surp... | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Let's see how things are shaping up for the company this quarter. Zacks Rank: Though AbbVie's Zacks Rank #3 increases the predictive power of the ESP, its -0.71% Earnings ESP makes the surprise prediction difficult. Click to get t... | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Let's see how things are shaping up for the company this quarter. Zacks Rank: Though AbbVie's Zacks Rank #3 increases the predictive power of the ESP, its -0.71% Earnings ESP makes the surprise prediction difficult. Click to get t... | AbbVie Inc.ABBV is scheduled to release second-quarter 2017 earnings, before the opening bell on Jul 28. AbbVie's shares have rallied 18.2% so far this year, while the industry has recorded an increase of 13.2%. We note that AbbVie's earnings history is a mixed bag as the pharmaceuticals company delivered positive surp... |
26,085 | 2017-07-21 00:00:00 UTC | Rothschild Investment Corp Buys United Parcel Service Inc, United Parcel Service Inc, Costco ... | ABBV | https://www.nasdaq.com/articles/rothschild-investment-corp-buys-united-parcel-service-inc-united-parcel-service-inc-costco | null | null | Rothschild Investment Corp
New Purchases: PEG , APO , CRM , CRM, HPQ, EZU, ACM, SIG, CME, FAST,
Added Positions:AXP, AXP, COST, NUE, GS, KRE, KITE, FEZ, TGT, AGN,
Reduced Positions:KR, BMY, BMY, F, F, CSCO, SO, RCL, HD, JPM,
Sold Out:UPS, TSLA, FMBI, USB, AON, MMC, WSTC, CBI, AZSEY, GPS,
For the details of ROTHSCHILD I... | Shares reduced by 0.32% AbbVie Inc ( ABBV ) - 188,123 shares, 1.74% of the total portfolio. Rothschild Investment Corp New Purchases: PEG , APO , CRM , CRM, HPQ, EZU, ACM, SIG, CME, FAST, Added Positions:AXP, AXP, COST, NUE, GS, KRE, KITE, FEZ, TGT, AGN, Reduced Positions:KR, BMY, BMY, F, F, CSCO, SO, RCL, HD, JPM, Sol... | Shares reduced by 0.32% AbbVie Inc ( ABBV ) - 188,123 shares, 1.74% of the total portfolio. Shares added by 1.03% New Purchase: Public Service Enterprise Group Inc (PEG) Rothschild Investment Corp initiated holdings in Public Service Enterprise Group Inc. New Purchase: Apollo Global Management LLC (APO) Rothschild Inve... | Shares reduced by 0.32% AbbVie Inc ( ABBV ) - 188,123 shares, 1.74% of the total portfolio. Rothschild Investment Corp New Purchases: PEG , APO , CRM , CRM, HPQ, EZU, ACM, SIG, CME, FAST, Added Positions:AXP, AXP, COST, NUE, GS, KRE, KITE, FEZ, TGT, AGN, Reduced Positions:KR, BMY, BMY, F, F, CSCO, SO, RCL, HD, JPM, Sol... | New Purchase: Salesforce.com Inc (CRM) Rothschild Investment Corp initiated holdings in Salesforce.com Inc. Shares reduced by 0.32% AbbVie Inc ( ABBV ) - 188,123 shares, 1.74% of the total portfolio. Shares added by 0.92% MetLife Inc ( MET ) - 238,944 shares, 1.67% of the total portfolio. |
26,086 | 2017-07-20 00:00:00 UTC | Is Gilead (GILD) Poised for a Beat This Earnings Season? | ABBV | https://www.nasdaq.com/articles/is-gilead-gild-poised-for-a-beat-this-earnings-season-2017-07-20 | null | null | Gilead Sciences Inc.GILD is scheduled to report second-quarter 2017 results on Jul 26, after the market closes . Last quarter, the company beat expectations by 0.92%.
Gilead Sciences, Inc. Price and EPS Surprise
Gilead Sciences, Inc. Price and EPS Surprise | Gilead Sciences, Inc. Quote
Gilead's track record is pretty m... | Harvoni and Sovaldi has been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR among others. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harv... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harv... | Harvoni and Sovaldi has been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR among others. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report... |
26,087 | 2017-07-19 00:00:00 UTC | Gilead's HCV Portfolio Receives a Boost With Vosevi Approval | ABBV | https://www.nasdaq.com/articles/gileads-hcv-portfolio-receives-a-boost-with-vosevi-approval-2017-07-19 | null | null | Gilead Sciences, Inc . GILD announced that the FDA has approved Vosevi (Sovaldi, velpatasvir 100 mg/voxilaprevir 100 mg) tablets. The drug is a single-tablet regimen (STR) for the re-treatment of chronic hepatitis C virus (HCV) infection in adults with genotype 1, 2, 3, 4, 5 or 6, previously treated with an NS5A inhibi... | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie... | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni, Sovaldi and Epcl... | Harvoni, Sovaldi and Epclusa has being facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY Daklinza and Johnson & Johnson's JNJ Olysio. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie... |
26,088 | 2017-07-19 00:00:00 UTC | Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2? | ABBV | https://www.nasdaq.com/articles/can-biogen-biib-keep-the-earnings-streak-alive-in-q2-2017-07-19 | null | null | Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, will report second-quarter 2017 results on Jul 25, before the market opens. Last quarter, the company delivered a positive earnings surprise of 4.63%.
Biogen's shares have declined 0.4% this year so far while the Zacks classified Biomed-Genetics... | Zinbryta, launched in collaboration with AbbVie Inc. ABBV in Aug 2016, is expected to continue to contribute to revenues in the U.S. and the EU. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Re... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta, launched in collaboration with AbbVie... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta, launched in collaboration with AbbVie... | Zinbryta, launched in collaboration with AbbVie Inc. ABBV in Aug 2016, is expected to continue to contribute to revenues in the U.S. and the EU. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Re... |
26,089 | 2017-07-18 00:00:00 UTC | Perrigo Company Gets FDA Approval for Generic Topical Gel | ABBV | https://www.nasdaq.com/articles/perrigo-company-gets-fda-approval-for-generic-topical-gel-2017-07-18 | null | null | Perrigo Company plc PRGO announced that it has received final approval from the FDA for its AB rated generic version of AbbVie Inc.'s ABBV Androgel Topical Gel. The drug is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Annual market sales f... | Perrigo Company plc PRGO announced that it has received final approval from the FDA for its AB rated generic version of AbbVie Inc.'s ABBV Androgel Topical Gel. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Perrigo Company (PRGO): Free Stock Analys... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Perrigo Company (PRGO): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company plc PRGO announced that it has recei... | Perrigo Company plc PRGO announced that it has received final approval from the FDA for its AB rated generic version of AbbVie Inc.'s ABBV Androgel Topical Gel. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Perrigo Company (PRGO): Free Stock Analys... | Perrigo Company plc PRGO announced that it has received final approval from the FDA for its AB rated generic version of AbbVie Inc.'s ABBV Androgel Topical Gel. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Perrigo Company (PRGO): Free Stock Analys... |
26,090 | 2017-07-18 00:00:00 UTC | 5 Big Pharma Stocks With the Best Drug Pipelines | ABBV | https://www.nasdaq.com/articles/5-big-pharma-stocks-best-drug-pipelines-2017-07-18 | null | null | Big pharma companies can't rest on their laurels. Continual research and development is critical to ensure long-term success. Some of that R&D pays off more than others, though.
Market research firm EvaluatePharma recently released its report looking at the state of the biopharmaceutical industry five years from now. O... | *Stock Advisor returns as of July 6, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. Here's why Roche (NASDAQOTH: RHHBY) , AstraZeneca (NYSE: AZN) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Johnson & Johnson (NYSE: JNJ) ranked at the top. AbbVie AbbVie's pipeline takes the third spot, w... | Here's why Roche (NASDAQOTH: RHHBY) , AstraZeneca (NYSE: AZN) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Johnson & Johnson (NYSE: JNJ) ranked at the top. AbbVie AbbVie's pipeline takes the third spot, with EvaluatePharma projecting total sales of $20.4 billion between now and 2022. Three candidates st... | Here's why Roche (NASDAQOTH: RHHBY) , AstraZeneca (NYSE: AZN) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Johnson & Johnson (NYSE: JNJ) ranked at the top. AbbVie AbbVie's pipeline takes the third spot, with EvaluatePharma projecting total sales of $20.4 billion between now and 2022. Three candidates st... | Here's why Roche (NASDAQOTH: RHHBY) , AstraZeneca (NYSE: AZN) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Johnson & Johnson (NYSE: JNJ) ranked at the top. AbbVie AbbVie's pipeline takes the third spot, with EvaluatePharma projecting total sales of $20.4 billion between now and 2022. Three candidates st... |
26,091 | 2017-07-18 00:00:00 UTC | Tealwood Asset Management Inc Buys Carnival Corp, Cypress Semiconductor Corp, Crown Castle ... | ABBV | https://www.nasdaq.com/articles/tealwood-asset-management-inc-buys-carnival-corp-cypress-semiconductor-corp-crown-castle | null | null | Tealwood Asset Management Inc
New Purchases: CCL , CY , CCI , NLSN, BIVV, PUMP, INGR, WRD, ROP, INFO,
Added Positions:HBI, DLPH, RMP, MRK, AMCX, ENB, PACW, TIVO, PFE, KHC,
Reduced Positions:PFG, TFX, JNJ, DLR, SYK, FIS, MTG, GLW, IAC, OTEX,
Sold Out:LAMR, GM, TU, SNCR, XOM, CVS,
For the details of TEALWOOD ASSET MANAGE... | Tealwood Asset Management Inc New Purchases: CCL , CY , CCI , NLSN, BIVV, PUMP, INGR, WRD, ROP, INFO, Added Positions:HBI, DLPH, RMP, MRK, AMCX, ENB, PACW, TIVO, PFE, KHC, Reduced Positions:PFG, TFX, JNJ, DLR, SYK, FIS, MTG, GLW, IAC, OTEX, Sold Out:LAMR, GM, TU, SNCR, XOM, CVS, For the details of TEALWOOD ASSET MANAGE... | Tealwood Asset Management Inc New Purchases: CCL , CY , CCI , NLSN, BIVV, PUMP, INGR, WRD, ROP, INFO, Added Positions:HBI, DLPH, RMP, MRK, AMCX, ENB, PACW, TIVO, PFE, KHC, Reduced Positions:PFG, TFX, JNJ, DLR, SYK, FIS, MTG, GLW, IAC, OTEX, Sold Out:LAMR, GM, TU, SNCR, XOM, CVS, For the details of TEALWOOD ASSET MANAGE... | Tealwood Asset Management Inc New Purchases: CCL , CY , CCI , NLSN, BIVV, PUMP, INGR, WRD, ROP, INFO, Added Positions:HBI, DLPH, RMP, MRK, AMCX, ENB, PACW, TIVO, PFE, KHC, Reduced Positions:PFG, TFX, JNJ, DLR, SYK, FIS, MTG, GLW, IAC, OTEX, Sold Out:LAMR, GM, TU, SNCR, XOM, CVS, For the details of TEALWOOD ASSET MANAGE... | Tealwood Asset Management Inc New Purchases: CCL , CY , CCI , NLSN, BIVV, PUMP, INGR, WRD, ROP, INFO, Added Positions:HBI, DLPH, RMP, MRK, AMCX, ENB, PACW, TIVO, PFE, KHC, Reduced Positions:PFG, TFX, JNJ, DLR, SYK, FIS, MTG, GLW, IAC, OTEX, Sold Out:LAMR, GM, TU, SNCR, XOM, CVS, For the details of TEALWOOD ASSET MANAGE... |
26,092 | 2017-07-18 00:00:00 UTC | Hendershot Investments Inc. Buys Walgreens Boots Alliance Inc, DXC Technology Co, Ross Stores ... | ABBV | https://www.nasdaq.com/articles/hendershot-investments-inc-buys-walgreens-boots-alliance-inc-dxc-technology-co-ross-stores | null | null | Hendershot Investments Inc.
New Purchases: DXC , ROST , PPL ,
Added Positions:WBA, DIS, GPC, FFIV, TJX, WHG, NKE, SBUX, CAKE, ACN,
Reduced Positions:BAX, BIIB, MO, JNJ, SYK, FLR, MA, PII, QCOM, INTC,
Sold Out:ABT, ACWI, BMY,
For the details of Hendershot Investments Inc.'s stock buys and sells, go to http://www.gurufoc... | Shares added by 0.56% AbbVie Inc ( ABBV ) - 147,373 shares, 5.07% of the total portfolio. Hendershot Investments Inc. New Purchases: DXC , ROST , PPL , Added Positions:WBA, DIS, GPC, FFIV, TJX, WHG, NKE, SBUX, CAKE, ACN, Reduced Positions:BAX, BIIB, MO, JNJ, SYK, FLR, MA, PII, QCOM, INTC, Sold Out:ABT, ACWI, BMY, For t... | Shares added by 0.56% AbbVie Inc ( ABBV ) - 147,373 shares, 5.07% of the total portfolio. Hendershot Investments Inc. New Purchases: DXC , ROST , PPL , Added Positions:WBA, DIS, GPC, FFIV, TJX, WHG, NKE, SBUX, CAKE, ACN, Reduced Positions:BAX, BIIB, MO, JNJ, SYK, FLR, MA, PII, QCOM, INTC, Sold Out:ABT, ACWI, BMY, For t... | Shares added by 0.56% AbbVie Inc ( ABBV ) - 147,373 shares, 5.07% of the total portfolio. Hendershot Investments Inc. New Purchases: DXC , ROST , PPL , Added Positions:WBA, DIS, GPC, FFIV, TJX, WHG, NKE, SBUX, CAKE, ACN, Reduced Positions:BAX, BIIB, MO, JNJ, SYK, FLR, MA, PII, QCOM, INTC, Sold Out:ABT, ACWI, BMY, For t... | Shares added by 0.56% AbbVie Inc ( ABBV ) - 147,373 shares, 5.07% of the total portfolio. Hendershot Investments Inc. New Purchases: DXC , ROST , PPL , Added Positions:WBA, DIS, GPC, FFIV, TJX, WHG, NKE, SBUX, CAKE, ACN, Reduced Positions:BAX, BIIB, MO, JNJ, SYK, FLR, MA, PII, QCOM, INTC, Sold Out:ABT, ACWI, BMY, For t... |
26,093 | 2017-07-18 00:00:00 UTC | Repros' Proellex Stays on Partial Clinical Hold, Shares Fall | ABBV | https://www.nasdaq.com/articles/repros-proellex-stays-on-partial-clinical-hold-shares-fall-2017-07-18 | null | null | Repros Therapeutics Inc.RPRX announced that it received preliminary feedback from the FDA on its clinical development program for Proellex to treat uterine fibroids by oral mechanism. Per the FDA's review, Proellex will remain on partial clinical hold and the company will be required to accumulate a large pre-approval ... | In Apr 2017, AbbVie Inc. ABBV along with Neurocrine Biosciencesis also evaluating elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids which is in mid-stage studies. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Repros Therapeutics Inc. (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. In Apr 2017, AbbVie Inc. ABBV along wit... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Repros Therapeutics Inc. (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. In Apr 2017, AbbVie Inc. ABBV along wit... | In Apr 2017, AbbVie Inc. ABBV along with Neurocrine Biosciencesis also evaluating elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids which is in mid-stage studies. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis ... |
26,094 | 2017-07-14 00:00:00 UTC | Notable ETF Inflow Detected - VHT, PFE, MDT, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-vht-pfe-mdt-abbv-2017-07-14 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $66.8 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 45,451,522 to 45... | Among the largest underlying components of VHT, in trading today Pfizer Inc (Symbol: PFE) is up about 0.5%, Medtronic PLC (Symbol: MDT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.3%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price perform... | Among the largest underlying components of VHT, in trading today Pfizer Inc (Symbol: PFE) is up about 0.5%, Medtronic PLC (Symbol: MDT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.3%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price perform... | Among the largest underlying components of VHT, in trading today Pfizer Inc (Symbol: PFE) is up about 0.5%, Medtronic PLC (Symbol: MDT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , ... | Among the largest underlying components of VHT, in trading today Pfizer Inc (Symbol: PFE) is up about 0.5%, Medtronic PLC (Symbol: MDT) is up about 0.4%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , ... |
26,095 | 2017-07-14 00:00:00 UTC | J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab | ABBV | https://www.nasdaq.com/articles/jj-jnj-gets-fda-nod-for-psoriasis-drug-guselkumab-2017-07-14 | null | null | Johnson &JohnsonJNJ , a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.
The drug was approved under an accelerated process, following the filing of a priority vo... | The VOYAGE 2 trial evaluated guselkumab versus AbbVie, Inc.'s ABBV Humira. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article... | The VOYAGE 2 trial evaluated guselkumab versus AbbVie, Inc.'s ABBV Humira. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article... | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The VOYAGE 2 trial evaluated guselkumab versus Ab... | The VOYAGE 2 trial evaluated guselkumab versus AbbVie, Inc.'s ABBV Humira. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article... |
26,096 | 2017-07-14 00:00:00 UTC | Can Novartis (NVS) Spring a Surprise This Earnings Season? | ABBV | https://www.nasdaq.com/articles/can-novartis-nvs-spring-a-surprise-this-earnings-season-2017-07-14 | null | null | Swiss pharmaceutical company Novartis AGNVS is scheduled to report second-quarter 2017 results on Jul 18.
A look at Novartis' share price movement year to date shows that the stock has outperformed the Zacks classified Large Cap Pharma industry. Its shares have rallied 13.3% compared with the industry's gain of 11.3%.
... | Cosentyx has been strong and the company has grabbed market shares from rivals like AbbVie's ABBV Humira and Amgen's AMGN Enbrel. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Rep... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Cosentyx has been strong and the c... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Cosentyx has been strong and the c... | Cosentyx has been strong and the company has grabbed market shares from rivals like AbbVie's ABBV Humira and Amgen's AMGN Enbrel. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Rep... |
26,097 | 2017-07-14 00:00:00 UTC | AbbVie Inc (ABBV) Stock Isn’t Done Charting New Highs Yet | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-stock-isnt-done-charting-new-highs-yet-2017-07-14 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) is part of a notoriously volatile sector even under normal circumstances. Add to it an election cycle where they've been the hottest political football and you get a sector wilder than the real running of the bulls in Pamplona.
Case... | Advanced Micro Devices, Inc. (AMD) Reveals Threadripper Price, Availability The Juice (Optional Upon Trigger): Buy ABBV stock Aug $75/$77.50 debit call spread which could cost 40 cents to open and deliver $2 in profits. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) is part of a... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) is part of a notoriously volatile sector even under normal circumstances. ABBV Stock Options The Trade: Sell ABBV stock Nov $65 put naked and collect 90 cents to open. Advanced Micro Devices, Inc. (AMD) Reveals Threadripper Price, A... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) is part of a notoriously volatile sector even under normal circumstances. ABBV Stock Options The Trade: Sell ABBV stock Nov $65 put naked and collect 90 cents to open. More From InvestorPlace 7 Blue-Chip Stocks at High Risk for Earn... | Case in point, ABBV stock is now 30% higher than last November and 60% since a year prior to that. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) is part of a notoriously volatile sector even under normal circumstances. ABBV is a fundamentally sound company and from a PE perspec... |
26,098 | 2017-07-13 00:00:00 UTC | Franklin Street Advisors Inc Buys Coca-Cola Co, JPMorgan Chase, Cisco Systems Inc, Sells ... | ABBV | https://www.nasdaq.com/articles/franklin-street-advisors-inc-buys-coca-cola-co-jpmorgan-chase-cisco-systems-inc-sells-2017 | null | null | Franklin Street Advisors Inc
New Purchases: SPGI , UNH , ABC , VEU, VFC,
Added Positions:KO, JPM, CSCO, SBUX, ABBV, MAT, ADS, CME, YUM, BLK,
Reduced Positions:GE, BMY, CLX, AAPL, RY, MCD, CALA, COH, NKE, GILD,
Sold Out:KSS, AKAM, HOG, ATRA, SLF, LLY, ADP, BLCM, MCHP, NOC,
For the details of FRANKLIN STREET ADVISORS INC... | Franklin Street Advisors Inc New Purchases: SPGI , UNH , ABC , VEU, VFC, Added Positions:KO, JPM, CSCO, SBUX, ABBV, MAT, ADS, CME, YUM, BLK, Reduced Positions:GE, BMY, CLX, AAPL, RY, MCD, CALA, COH, NKE, GILD, Sold Out:KSS, AKAM, HOG, ATRA, SLF, LLY, ADP, BLCM, MCHP, NOC, For the details of FRANKLIN STREET ADVISORS INC... | Franklin Street Advisors Inc New Purchases: SPGI , UNH , ABC , VEU, VFC, Added Positions:KO, JPM, CSCO, SBUX, ABBV, MAT, ADS, CME, YUM, BLK, Reduced Positions:GE, BMY, CLX, AAPL, RY, MCD, CALA, COH, NKE, GILD, Sold Out:KSS, AKAM, HOG, ATRA, SLF, LLY, ADP, BLCM, MCHP, NOC, For the details of FRANKLIN STREET ADVISORS INC... | Franklin Street Advisors Inc New Purchases: SPGI , UNH , ABC , VEU, VFC, Added Positions:KO, JPM, CSCO, SBUX, ABBV, MAT, ADS, CME, YUM, BLK, Reduced Positions:GE, BMY, CLX, AAPL, RY, MCD, CALA, COH, NKE, GILD, Sold Out:KSS, AKAM, HOG, ATRA, SLF, LLY, ADP, BLCM, MCHP, NOC, For the details of FRANKLIN STREET ADVISORS INC... | Franklin Street Advisors Inc New Purchases: SPGI , UNH , ABC , VEU, VFC, Added Positions:KO, JPM, CSCO, SBUX, ABBV, MAT, ADS, CME, YUM, BLK, Reduced Positions:GE, BMY, CLX, AAPL, RY, MCD, CALA, COH, NKE, GILD, Sold Out:KSS, AKAM, HOG, ATRA, SLF, LLY, ADP, BLCM, MCHP, NOC, For the details of FRANKLIN STREET ADVISORS INC... |
26,099 | 2017-07-12 00:00:00 UTC | Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label | ABBV | https://www.nasdaq.com/articles/amgen-gets-fda-nod-to-broaden-leukemia-drug-blincytos-label-2017-07-12 | null | null | Amgen Inc.AMGN announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been accepted by the FDA.
So far this year, Amgen's shares are up 18.5%, outperforming the 7.1% increase registered by the Zacks classified Biomed/Geneti... | Amgen's pipeline updates have been impressive so far this year with positive data from various studies and approval for Parsabiv for secondary hyperparathyroidism; Amgevita, a generic version of AbbVie Inc.'s ABBV Humira, for all available indications in Europe; Vectibix in metastatic colorectal cancer and the latest l... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen's pipeline updates have been impressive so fa... | Amgen's pipeline updates have been impressive so far this year with positive data from various studies and approval for Parsabiv for secondary hyperparathyroidism; Amgevita, a generic version of AbbVie Inc.'s ABBV Humira, for all available indications in Europe; Vectibix in metastatic colorectal cancer and the latest l... | Amgen's pipeline updates have been impressive so far this year with positive data from various studies and approval for Parsabiv for secondary hyperparathyroidism; Amgevita, a generic version of AbbVie Inc.'s ABBV Humira, for all available indications in Europe; Vectibix in metastatic colorectal cancer and the latest l... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.